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IDENTIFIKASI DEFEK GENETIK  PADA   
 X-LINKED MENTAL RETARDATION 
 
 
Latar Belakang: X-linked mental retardation (XLMR) berperan pada 40% pria penderita 
retardasi mental (RM). Defek genetik berperan pada 50% kasus MR. Terdapat 56 loci 
XLMR  non-sindromik  (MRX)  dan  35  loci  XLMR-sindromik  (MRXS)  yang  belum 
diketahui gen penyebabnya.  
 
Tujuan: Identifikasi defek genetik pada keluarga XLMR. 
 
Metode:  Pemeriksaan  klinis  dan  analisis  sitogenetik  konvensional  dilakukan  pada  4 
keluarga MRXS dan 6 keluarga MRX, dilanjutkan analisis pengulangan CGG pada regio 
promoter  FMR1.  Analisis  linkage  dilakukan  dengan  STR-markers  polimorfik  pada 
kromosom X dilanjutkan perhitungan skor LOD. Dilakukan pemeriksaan status inaktivasi 
kromosom X wanita pembawa dengan metode FMR1 dilanjutkan metode AR bila tidak 
informatif untuk FMR1. Dilakukan pemilihan kandidat gen dalam linkage interval dan 
analisis mutasi. 
 
Hasil:  Tidak  dijumpai  adanya  kelainan  kromosom  numerikal  dan  Fragile-X  pada  10 
keluarga  ini.  Terdapat  variasi  linkage  interval  antara  20  Mb  hingga  121  Mb.  Tidak 
terdapat mutasi HSD17B10, UBQLN2, SYP, ARGHEF pada keluarga W92-053 (XLMR 
dan hipomielinasi). Tidak terdapat mutasi SLITRK2 dan SLITRK4 pada keluarga P03-
0452  dan  13753/HC  (XLMR  dan  hidrosefalus).  Tidak  terdapat  mutasi  GPC3  pada 
keluarga DF27004 (XLMR dan pertumbuhan berlebih). Keluarga W092-053, PO3-0452, 
DF27004,  dan  W08-2152  menunjukkan  penyimpangan  inaktivasi  kromosom-X    pada 
wanita pembawa.   
 
Kesimpulan:  Identifikasi  defek  genetik  pada  sepuluh  keluarga  menunjukkan  linkage 
interval yang bervariasi besarnya dari 20 Mb hingga 121 Mb dengan skor LOD 0,17 
hingga  3,3,  penyimpangan  inaktivasi  kromosom-X  pada  empat  keluarga,  dan  tidak 
terdapat mutasi pada kandidat gen. Analisis STR markers bermanfaat untuk menentukan 
linkage interval, mempersempit daerah yang akan diteliti, dan untuk konseling genetika.   
 
Kata kunci: X-linked mental retardation, defek genetik, analisis linkage, analisis mutasi 
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IDENTIFICATION OF GENETIC DEFECTS INVOLVED IN 
X-LINKED MENTAL RETARDATION 
 
  
Backgrounds: X-linked mental retardation (XLMR) has been the focus of MR research 
because of 40% excess of males with MR. Genetic defects are estimated to account 
for 50% MR cases. There are still 56 non-syndromic (MRX) and 35 syndromic XLMR 
(MRXS) loci with unknown causative genes.   
 
Aims: Identification of the genetic defects in XLMR families. 
 
Methods:  Four  MRXS  and  6  MRX  families  were  studied.  Clinical  dysmorphologic 
examination and conventional cytogenetic analysis were performed followed by Fragile-
X exclusion. Linkage analysis was conducted with highly polymorphic STR-markers on 
the X-chromosome followed by LOD scores calculation. An FMR1 X-inactivation assay 
was performed in 15 females from all families, followed by AR method if the result were 
uninformative for FMR1. Candidate genes were selected in linkage interval and mutation 
analysis was performed. 
 
Results: Gross numerical chromosomal abnormalities and Fragile-X were excluded in all 
10  families.  Ten  XLMR  families  showed  intervals  varying  from  20  Mb  to  121  Mb. 
Family  W92-053  (mental  retardation  and  hypomyelination)  showed  no  mutation  in 
HSD17B10,  UBQLN2,  SYP,  ARGHEF.  Two  families  with  MR  and  congenital 
hydrocephalus  (P03-0452  and  13753/HC)  showed  no  mutations  in  SLITRK2  and 
SLITRK4.  Family  DF27004  (MR  and  overgrowth  features)  showed  no  mutations  in 
GPC3.  Family  W092-053,  PO3-0452,  DF27004,  and  W08-2152  showed  skewed  X-
inactivation in the obligate carrier female. 
 
Conclusions:  Genetic  defects  identification  in  ten  families  showed  varying  linkage 
intervals from 20 Mb to 121 Mb with varying LOD scores from 0,17 to 3.3, skewed X-
inactivation in 4 families, and no mutation in the candidate genes. STR markers analysis 
was useful in determining linkage intervals, narrowing down the region of interest for 
further studies, and genetic counselling. 
 
Keywords:  X-linked  mental  retardation,  genetic  defects,  linkage  analysis,  mutation 
analysis  
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CHAPTER I 
INTRODUCTION 
 
I.1 Backgrounds 
Mental Retardation (MR) is defined by IQ below 70 and adaptive behavior 
limitations, which manifest before 18 years of age (Schalock et al. 2007). The 
prevalence of mental retardation is estimated to be about 1 to 3% of the general 
population (Brosco et al. 2006). Mental retardation is the most common reason for 
referral  to  genetic  services  and  one  of  the  important  unsolved  problems  in 
healthcare (de Vries et al. 1997; Yeargin-Allsopp et al. 1997). Genetic defects are 
estimated to account for approximately 50% of cases (Leonard and Wen, 2002). 
Genetic  defects  in  MR  consist  of  chromosomal  abnormalities  (structural  and 
numerical),  single  gene  disorders,  and  multifactorial  defect  (Basel-Vanegeite, 
2008). 
X-linked mental retardation (XLMR) is characterized as mental retardation 
with a distinctive pattern of inheritance, associated with X-chromosome (Ijntema, 
2001). XLMR has been the focus of MR research for over three decades because 
of the fact that there is 40% excess of MR males  (Yeargin-Allsopp et al. 1997; 
Leonard  and  Wen,  2002).  In  this  case,  linkage  to  the  X-chromosome  can  be 
established in families with only 2 male patients and one obligate female carrier, 
such as nephew uncle families.  In addition, instead of the whole genome, only X-
chromosome  needs  to  be  considered  (de  Brouwer  et  al.  2007).    XLMR  is  a 
heterogeneous disorder for which many of the causative genes are still unknown, 
although  69  genes  have  been  identified  as  causing  syndromic  XLMR  and  33 
genes as causing non syndromic XLMR (18 causing both syndromic and non-
syndromic XLMR) (Greenwood Genetic Center, 2010). However, there are still 
56 non syndromic and 35 syndromic XLMR loci for which the gene defect is still 
unknown  (Gecz  et  al.  2009).  It  is  assumed  that  most  of  these  loci  represent 
separate, novel XMLR genes, suggesting that there are still more than 80 MR 
genes to be disclosed on the X chromosome alone (de Brouwer et al. 2007).  2 
 
Genetic defect identification in MR is a challenging process. The first step 
in elucidating genetic defect in MR is a thorough clinical work-up, which could 
screen  acquired  factor  from  anamnesis  and  also  largely  known  syndrome  for 
example Down Syndrome and Fragile X from the clinical features (Lugtenberg et 
al. 2006). The pedigree taken also could show the possible mode of inheritance of 
the  disorder.  The  next  step  is  exclusion  other  cause  of  mental  retardation. 
Considering the large role of chromosomal aberration in MR (11%; Stevenson et 
al.  2003),  in  the  following  step  patients  are  routinely  screened  for  large 
chromosomal aberration by conventional karyotyping.  In addition, considering 
that Fragile X is the most common inherited MR syndrome with incidence of 
1/3000  male,  in  the  next  step  all  the  patients  are  screened  for  CGG  repeat 
expansion in 5’ untranslated region of FMR1 that cause Fragile X syndrome (de 
Vries et al. 1997). Before researchers could identify and finally sequence the gene 
responsible for a disease, the gene location first must be mapped in the genome. 
Linkage analysis is a method that allow to rule out regions of chromosomes that 
are likely to contain a risk gene in the linkage interval, and determine areas where 
there is a low chance of finding a risk gene (Massanet, 2009). This approach use 
the  polymorphism  character  of  microsatellite  markers  (STRs:  short  tandem 
repeats) -a short blocks (often less than 150 bp) of simple repetitive sequences (1-4 bp) 
dispersed randomly across all chromosomes- for mapping the linkage interval (Stopps 
and  McDonald,  1998).  Once  a  linkage  interval  is  located  in  a  chromosome, 
candidate genes within the interval could be selected based on its characteristics, 
for  example  its  expression  in  brain,  inactivation  status  by  X  chromosome 
inactivation (XCI) mechanism, homology to known MR genes, etc (Lugtenberg et 
al. 2006). This approach is called positional candidate gene analysis approach, 
which is assumed to be able to largely reduce cost needed compared to screening 
the whole genomes (Stratchan and Read, 1999).  
National Survey, SUSENAS in 2000 reported 384.818 person with MR in 
Indonesia (0,19% (National Survey, 2000)). Underreporting is likely considering 
the widespread stigma (Komardjaja, 2005; Gabel, 2004) and discrimination (Kats, 
2008; Croot, 2008) that people with disabilities and their families have to endure 3 
 
in Asian cultures and the lack of research on mental retardation in Indonesia.  As a 
developing  country,  there  is  no  health  care  insurance  system  for  all  citizens 
making  costs  for  medical  care  for  MR  patients  unbearable  for  their  families. 
Associated mental impairment, high risk of recurrence, and no therapy available 
makes genetic counseling essential for families with mental retardation to prevent 
recurrence of similarly affected children in the family. The understanding of the 
molecular basis of MR will lead to improvement in diagnostic testing, genetic 
counselling and also future therapeutics (Basel-Vanagaite, 2008). In contrast to 
the extensive research performed on XLMR in European countries, so far there 
are  only  a  few  XLMR  studies  performed  in  the  Indonesian  population,  for 
example Fragile X screening by Faradz et al in 1998 and subtelomeric duplication 
screening by Mundhofir et al 2008, and no study about other XLMR. Currently, 
there are no researchprotocols  nor diagnostic workflows for XLMR  in general in 
Indonesia. Thus, this study aims to identify genetic defects involved in XLMR by 
using positional candidate gene analysis approach which can be used for genetic 
counselling purposes and to set up a basic workflow for future XLMR studies in 
Indonesia.   
 
I.2 Research questions     
I.2.1. General research question                     
What genetic defects found in the XLMR families of this study? 
I.2.2. Specific research questions   
1.  What linkage intervals do we observe in  the XLMR families? 
2.   What  is  the  X-inactivation  status  of  the  females  carriers  within  these  
families? 
3.  What are the best candidate genes within the linkage intervals in these 
families? 
 
I.3 Research purposes 
I.3.1. General research purposes  
Identification of genetic defects in X-linked mental retardation in families.   4 
 
 
I.3.2. Specific research purposes 
1.  Identify linkage intervals within XLMR families. 
2.  Measure X-inactivation status of the females carriers in these families. 
3.  Select new candidate genes within the linkage intervals in these families. 
 
I.4 Research advantages 
1.  This study will contribute to the understanding of the molecular basis of 
MR in XLMR families 
2.  Considering the current absence of an XLMR workflow in research and 
diagnostics  in  Indonesia,  this  study  will  establish  a  starting  point  for 
XLMR  research  and  diagnostics  by  developing  the  first  steps  for  a 
diagnostic workflow for XLMR in Indonesia. 
3.  Linkage result from this study will help to show potential carrier which 
can be used to perform genetic counselling prevent recurrence of similarly 
affected children in the family 
4.  The technical knowledge, gained by this research will help to introduce 
new techniques in genetic research in Semarang: e.g linkage analysis by 
STR-markers. 
5.  Regarding  the  limited  XLMR  research  in  Indonesia,  this  study  will 
encourage  other  researchers  to  perform  further  studies  in  mental 
retardation in Indonesia. 
 
I.5 Research originality 
1.  To our knowledge this is the first study in Indonesia to identify the genetic 
defects that cause X-linked mental retardation in Indonesian patients by 
using linkage analysis. 
2.  Screening  of  Fragile-X  and  conventional  cytogenetic  abnormalities  in 
individual with mental retardation in Indonesia have been performed by 
Faradz et al in 1998, but no other study known about other XLMR in 
Indonesia. 5 
 
3.  Mundhofir et al.in 2008 performed population screening of chromosomal 
abnormalities, CGG repeat expansion in FMR1, subtelomeric deletion and 
duplication  (STD),  and  Prader  Willy/Angelman  Syndrome  in  mentally 
retarded pupil in Semarang.  No other study known about other MR in 
Indonesia. 
 
Table1. Research originality in matriks form 
Title  Author  Method  Result 
Fragile  X 
Mental 
Retardation 
and  Fragile  X 
Chromosome 
in  Indonesian 
Population 
Faradz et al, 
1998 
Descriptive 
study  on  large 
population  to 
screen 
chromosomal 
abnormality, 
CGG  repeat  of 
FMR1  in 
Indonesian 
population. 
Fragile  X  prevalence 
in  Indonesia  is  about 
1.6-2%,  which  is 
significantly  different 
from  Kaukasian 
population 
X-Linked 
Mental 
Retardation:  A 
clinical  and 
molecular 
study 
Hamel  et 
al., 1999 
Descriptive 
study  on  13 
Dutch large thre 
degree  families 
with XLMR 
From  13  families, 
FRAXE  was 
segregated  in  one 
family,  one  mutation 
of  RaBGD11  was 
found  in  one  family, 
LOD score more than 
two was found in the 
rest of the family.  
Mutation 
Frequencies of 
X-linked 
Mental 
Retardation 
Genes in 
Families from 
the EuroMRX 
Consortium 
De Brouwer 
et al., 2007 
Descriptive 
study about  
mutation 
analysis in 400 
XLMR families 
from EuroMRX 
Consortium.  
 
For 42% of the 
families with obligate 
female carriers MR 
phenotype could be 
explained by a 
mutation.  
There was no 
difference between 
families with (lod 
score >2) or without 
(lod score <2) 
significant linkage to 
the X 
chromosome. 
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Title  Author  Method  Result 
Cytogenetics, 
molecular  and 
clinical  studies 
among 
mentally 
retarded 
individual  in 
Semarang 
Mundhofir 
et al., 2008 
Description 
study  about 
population 
screening  of 
chromosomal 
abnormality, 
CGG  repeat  of 
FMR1, 
subtelomeric 
deletion  and 
duplication 
(STD),  Prader 
Willy  and 
Angelman 
Syndrome 
(PW/AS)  using 
MLPA  in 
Semarang. 
From  122  mentally 
retarded  pupils,  1 
patient  showed  fully 
CGG  repeat 
expansion  ,  13 
patients showed STD, 
and  none  of  patients 
showed PW/AS 
 7 
 
CHAPTER II 
LITERATURE REVIEW 
 
 
II.1. Mental Retardation 
II.1.1. Definition 
Mental retardation has been classified as disease category three decades 
ago. According to DSM-IV in 1994, American Psychiatric Association defines 
mental retardation as sub average intellectual functioning and concurrent deficits 
or impairments in present adaptive functioning in at least two of the following 
skill areas: communication, self-care, home living, social/interpersonal skills, use 
of community resources, self-direction, functional academic skills, work, leisure, 
health, and safety with onset before 18 years (APA, 1994).  In 1996, WHO in the 
guideline ICD-10, described mental retardation as a reduced level of intellectual 
functioning, which decrease the ability to adapt with the daily needs of normal 
social environment (WHO, 1996). Nowadays, we used definition developed by 
AAMR  on  the  2002  AAMR  Manual,  which  describe  mental  retardation  as 
significant limitation in both intellectual functioning and adaptive behavior, which 
presents before age of 18 (Luckasson et al. 2002). Lately, term of “intellectual 
disability” is increasingly being used instead of “mental retardation” (Schallock et 
al. 2007).   
 
II.1.2. Classification 
There are several classification system of intellectual disability that are 
currently  used.  The  first  classification  is  developed  by  WHO  on  1996,  and 
summarized in ICD-10. WHO classified intellectual disability in axis I of five 
axes of ICD-10 as:  mild (IQ 50-69), moderate (IQ 35-49), severe (IQ 20-34), and 
profound (IQ under 20) (WHO, 1996). The second classification is developed by 
American  Psychiatric  Association  on  2002  in  multiaxial  system  DSM-IV  TR, 
which divided intellectual disability as mild (IQ 50-55 to 70), moderate (IQ 35-40 
to 50-55), severe (IQ 20-25 to 35-40), profound (IQ below 20 or 25), and severity 8 
 
unspecified  (strong  presumption  of  MR  but  the  intellegence  untestable  by 
standard test) (First, 2004).    
Based on the clinical features, intellectual disability could also be divided 
into  syndromic  and  non  syndromic  form.  Syndromic  forms  of  MR  are 
characterized by MR accompanied by either malformations, dysmorphic features, 
or  neurological  abnormalities.  Non  syndromic  MR  are  characterized  by  MR 
without  any    additional  features  (Basel-Vanagaite,  2008).  Nowadays,  the 
boundary  between  syndromic  and  non  syndromic  forms  of  MR  is  becoming 
blurred due to the finding that  in several genes, different mutations in the same 
gene can result in both syndromic and non syndromic form of MR (Frints, 2002). 
 
II.1.3 Prevalence 
In 2002, Leonard et al made a meta-analysis about MR prevalence, and 
estimated that MR is affecting 1-3% of general population (Leonard and Wen, 
2002). The prevalence of intellectual disability in Asia seemed to be consistent 
with Western population, which account about 0, 06-1,3% of total population, 
except for China (6,68%) (Jeevanandam, 2009). 
 
II.1.4. Etiology 
The  etiology  factors  of  mental  retardation  is  heterogeneous.  In  2003, 
Stevenson et al, based on a study cohort of 10,997 individuals with MR,  found 
that, a specific cause for the MR could be found in  43.5%  of the cohort and that  
genetic causes accounted for 28% of all cases and 63% of cases in which the 
cause could be identified (Figure 1; Stevenson et al. 2003) 9 
 
 
Figure 1.  Etiology of mental retardation (adopted from Stevenson et al, 2003) 
 
The etiology of intellectual disability are basically categorized as genetic, 
acquired, and unknown causes  (Moog, 2005). Acquired  causes of  MR  can  be 
divided  based  on  the  timing  of  defect as:  prenatal  (for  example: fetal  alcohol 
syndrome,  teratogen  exposure,  toxoplasmosis),  perinatal  (for  example: 
intrapartum  metabolic  acidosis,  early  onset  severe  neonatal  encepalopathy, 
perinatal  distress),  and  post  natal  (for  example:  traumatic  brain  damage,  lead 
intoxication)  (Moog,  2005).  Genetic  causes  of  MR  include  chromosomal 
abnormalities, monogenic disorder, and multifactorial causes (Figure 2;  Moog, 
2005; Basel-Vanegeite, 2008). 
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Figure  2.  Main  genetic  causes  of  mental  retardation  (Adopted  from  Basel-
Vanegeite, 2008) 
 
Chromosomal abnormalities as a cause of intellectual disability has been 
recognized  for  many  years.  Trisomy  21  that cause  Down  syndrome  is one  of 
recurrent  chromosomal  abnormality  that  cause  mental  retardation  with  the 
incidence of 1/600 newborns (Hulten et al. 2008). Chromosomal abnormalities 
cause  cognitive  impairment,  which  is  also  frequently  with  defects  of  heart 
formation  and  dysmorphic  features  (Raymond  and  Tarpey,  2006),    which 
represent  the  most  frequent  cause  of  syndromic  MR  (Basel-Vanegeite,  2008). 
Chromosome abnormalities with size of 3-5 megabases (Mb)  can be detected by 
conventional microscopic analysis of chromosomes isolated from peripheral blood 
lymphocytes in ∼5% of patients with unexplained MR (Anderson et al. 1996; de 
Vries et al. 1997). In the early 1990s, with the introduction of fluorescence in situ 
hybridization  (FISH),  recurrent  small  microdeletions  of  the  genome  (with 
maximum resolutin of 150 kb) not visible by light microscopy were identified 
associated with characteristic syndromic MR (Raymond and Tarpey, 2006). By 
the development of molecular cytogenetic techniques, such as FISH and multiplex 
ligation-dependent  probe  amplification  (MLPA)  (Schouten  et  al.  2002),  it  is 
shown that causative submicroscopic rearrangements of the subtelomeric regions 
can be found in ∼5% of patients with human malformations and MR (Koolen et 11 
 
al.  2004).  In  2005,  Van  Karnebeek  estimated  that  the  frequency  of  deteced 
chromosomal abnormalities is about  10%, ranging from 2% to 50% depending on 
the variation in the study design among published report. (Van Karnebeek, 2005). 
Nowadays,  the  focus  of  MR  research  has  been  shifted  to  identify  smaller 
chromosome abnormalities associated with disease, especially after introduction 
of high-resolution array.  During the past three years, numerous copy number 
variations  (CNVs)  have  been  identified  that  are  associated  with  MR  and 
developmental delay  (Stankiewicz and Beaudet, 2007). Zahir and Friedman  in 
2007 estimated that pathogenic CNVs can be found in 10–15% of individuals with 
idiopathic mental retardation (Zahir and Friedman, 2007). By the development of 
array technology, even it is assumed that up to 25% of all cases of MR may be 
explained by copy number-dependent gene dosage variations, although not all of 
these  variants  will  be  fully  penetrant,  which  create  a  challenge  in  clinical 
interpretation (Vissers et al. 2009). 
Monogenic  disorders  include  autosomal  dominant  disorders,  autosomal 
recessive  disorders,  and  X-linked  disorders.  Single-gene  disorders  have  been 
increasingly  recognized  to  cause  MR  over  the past  half  century.  Searching  in 
McKusick catalogue of genes and phenotypes (Online Mendelian Inheritance in 
Man (OMIM); OMIM, 2010) on January 2010 show 1629 entries associated with 
“mental retardation”. In cohort study of 10,997 individuals with MR in 2003 by 
Stevenson et al, it was found that 8%  of MR in the cohort was caused by single-
gene disorders. 
 
II.2. X-Linked Mental Retardation 
II.2.1. Definition 
XLMR is defined as proportion of mental retardation indicating distinctive 
pattern of inheritance associated with X-chromosome (Ijntema, 2001). General 
characteristic  of  XLMR  recessive  inheritance  are  demonstrating  the  following 
pattern: (Kingston, 2002)   
−  Only male affected almost exclusively. 
−  Transmission through carrier females. 12 
 
−  No male to male transmission.  
−  All daughters of affected males will be carriers. 
 
II.2.2. Prevalence  
Contribution  of  X-chromosome  mutations  to  the  spectrum  of  mental 
retardation has become subject of interest for many years. It was Penrose in 1938 
who  reported  for  the  first  time  that  mental  retardation  is  significantly  more 
common in males than in females, with the ratio of affected males to females 
being 1.3:1 (Penrose, 1938). Following studies  described large families with X-
linked inheritance pattern arising concept that X-linked genetic defects play an 
important role in the etiology of MR.  It was predicted that XLMR (including 
monogenic and multiple gene XLMR) might be contribute to up to 20-25% of 
mental  retardation  (Turner,  1996).  In  2005,  Roper  and  Hamel  predicted  that 
monogenic XLMR might be contribute to up to 10-15% of mental retardation 
(Ropers  and  Hamel,  2005).  In  1980,  Herbst  and  Miller  estimate  that  the 
prevalence of XLMR was about 1.83/1000 males (Herbst and Miller, 1980), with 
the fragile-X syndrome being considered as the most prevalent condition (20% of 
all XLMR cases) (Fishburn,1983).  Later on, the estimation was reduced into  10–
12% of all MR cases in males by the finding of a much smaller contribution of 
individual genes other than FMR1, to XLMR (Mandel and Chelly, 2004; Ropper 
and Hamel, 2005).   
 
II.2.3. Classification of XLMR 
Kerr in 1991 suggested classification of XLMR into syndromic (MRXS) 
and non-syndromic (MRX) (Kerr, 1991). Syndromic MRXS refers to condition 
associated  with  distinctive  clinical  features.  Nonsyndromic  MRX  is  associated 
with nonprogressive condition that affects cognitive function without any other 
distinctive features (Gecz and Mulley, 2000).  Trinucleotide repeat expansion on 
FMR1  gene  that cause Fragile  X  syndrome  is generally  regarded as  the  most 
common  cause  of  XLMR  with  the  prevalence  of  1/4000-1/8000  (Hagerman, 
2008). Nowadays, at least 215 different monogenic  X-linked mental retardation 13 
 
disorders have been described : 149 with specific clinical findings, including 98 
syndromes and 51 neuromuscular conditions, and 66 nonspecific (MRX) forms 
(Chiurazzi  et  al.  2008).  More  than    90  XLMR-associated  genes  have  been 
identified, which at least 53 were for syndromic, 27 for nonsyndromic, and 11 for 
both syndromic and nonsyndromic forms of mental retardation, which show the 
heterogeneity of XLMR (Figure 3; Table 2; Chiurazzi et al., 2008; Tarpey et al., 
2009; Greenwood Genetic Center 2010; XLMR Website 2010).  
 
II.2.4. Identification of genetic defects involved in XLMR 
The effort to identification genetic defects involved in XLMR has been 
developed since many years ago. There are several methods developed to address 
this effort, namely positional cloning, candidate gene, mutation analysis of the 
known gene, array method, and the newest, next generation sequencing. 
II.2.4.1. Positional Cloning 
Positional  cloning  is  intended    to  localize  determinants  of  disease 
susceptibility in the DNA sequence prior to determining their function (Maniatis 
et  al.,  2004).  This  method  identifies  a  disease  gene  based  on  no  information 
except its approximate chromosomal location. Linkage mapping is routinely used 
to  get  the  position  information.  In  this  method,  it  is  important  to  define  the 
candidate  region  as  tightly  as  possible,  considering  the  disadvantage  of  this 
method  of  being  expensive  and  time-  and  resource-  consuming  (Strachan  and 
Read, 1999; Zhu and Zhao, 2007). 
Later on, it was found that chromosomal aberrations can provide a useful 
short-cut to locating a disease gene. Translocation could give a chance to clone 
the X-chromosome gene which is disrupted by the translocation (Strachan and 
Read,  1999).  Small-scale  deletions  (microdeletions)  are  also  valuable  for 
positional cloning in which the deletion could encompass gene that cause XLMR. 
Using positional cloning methods, several MRX genes have been identified, for 
example:  FMR2  (Knight  et al,  1994),  ZNF81(Kleefstra  et  al.,  2004),  OPHN1, 
TM4SF2, IL1RAPL1, and ARHGEF6 (Ijntema 2001).   
 14 
 
 
Figure 3. Ideogram of human X-chromosome showing genetic heterogeneity of 
XLMR.  Genes  in  left  side  are  currently  known  to  be  mutated  in  NS-XLMR 
(n=38). Genes in the right side are known to be mutated in syndromic XLMR 
(n=52). Vertical lines shows linkage interval in MRX families. Asterisks sign near 
the  gene  names  show  genes  which  is  mutated  in  both  syndromic  and  non-
syndromic XLMR (n=11) (adopted from Gecz, 2009). 
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Table 2. Genes known to be mutated in non syndromic XLMR   
Gene 
Symbol 
Gene Name  Protein Function  Years 
 Found 
References 
AFF2 
(FMR2) 
FMR2 family, 
member 2 
Transcription 
regulation 
1996  Gecz et al. 1996 
Bensaid  et al. 2009 
OPHN1  Oligophrenin 1  Axon guidance, 
signal transduction, 
Rho-GTPase-
activating protein 
1998  Billuart et al. 1998 
PAK3  p21 protein 
(Cdc42/Rsc)-
activated kinase 3 
Axon guidance, 
signal transduction, 
actin cytoskeleton 
regulation 
1998  Allen et al. 1998 
GDI1  GDP dissociation 
inhibitor 1 
Signal transduction, 
regulation of GTPase 
activity 
1998  D’Adamo et al. 1998 
RPS6KA3  Ribosomal protein 
S6 kinase, 90kDa, 
polypeptida 3 
Kinase, post-
transitional 
modification 
1999  Merienne et al. 1999 
MECP2  Methyl-CpG binding 
protein 2 
Transcription 
regulation 
1999  Amir et al. 1999 
Orrico et al. 2000 
IL1RAPL1  Interleukin 1 
receptor accessory 
protein-like 1 
Signal transduction; 
innate immune 
response 
1999  Carrie et al. 1999 
ATRX  α-thalassemia-
mental retardation, 
X-linked 
Transcription 
regulation, chromatin 
remodelling protein 
2000  Gibbons and Higgs, 
2000 
ARHGEF6  Rac/Cdc42 guanine 
nucleotide exchange 
factor 6 
Actin cytoskeleton 
regulation 
2000  Kutsche et al. 2000 
TM4SF2  Transmembrane 4 
superfamily member 
2 
Signal transduction, 
neurite outgrowth, 
integrin binding 
2000  Zemni et al. 2000 
SLC6A8  Solute carrier family 
6 (creatine), member 
8 
Sodium ion transport, 
neurotransmitter 
transport, muscle 
contraction 
2002  Hahn  et al. 2002 
FGD1  FYVE, RhoGEF and 
PH-domain-
containing 1 
Actin cytoskeleton 
regulation, Rho/Rac 
guanine nucleotide 
exchange factor 
2002  Lebel  et al. 2002 
ARX  Aristaless-related 
homeobox 
Transcription 
regulation 
2002  Stromme et al. 2002 
ACSL4  Acyl-CoA synthetase 
long chain family 
member 4 
Fatty acid 
metabolism, fatty-
acid-coenzyme A 
ligase 
2002  Meloni et al. 2002 
AGTR2  Angiotensin II 
receptor type 2 
G-protein signalling, 
renin angiotensin 
system 
2002  Vervoort et al. 2002 
ZNF41  Zinc finger protein 
41 
Transcription 
regulation 
2003  Shoichet et al. 2003 
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Gene 
Symbol 
Gene Name  Protein Function  Years 
 Found 
References 
PQBP1  Polyglutamine-
binding protein 1 
Transcription 
regulation 
2003  Kalscheuer  et al. 2003 
NLGN4X  Neuroligin 4, X-
linked 
Cell adhesion 
molecule 
2003 
2004 
Jamain  et al. 2003 
NLGN3  Neuroligin 3  Cell adhesion 
molecule, synaptic 
transmission 
2003  Laumonnier  et al. 2004 
ZNF81  Zinc finger protein 
81 
Transcription 
regulation 
2004  Kleefstra et al. 2004 
 
DLG3  Dics, large homolog 
3 
Signal transduction, 
kinase, NMDA 
receptor localization 
2004  Tarpey et al. 2004 
FTSJ1  Ftsj homolog 1  Nucleolar protein, 
modification of 
rRNA 
2004  Freude et al. 2004 
JARID1C  Jumonji, AT rich 
interact domain 1C 
Transcription 
regulation, 
chromatine modifier 
2005  Jensen et al. 2005 
SHROOM4  Shroom family 
member 4 
Cytoskeletal 
architecture, protein-
protein interaction 
2006  Hagens  et al. 2006 
ZNF674  Zinc finger family 
member 674 
Transcription 
regulation 
2006  Lugtenberg et al. 2006 
AP1S2  Adaptor-related 
protein complex 1. 
sigma 2 subunit 
Recruits clathrin to 
vesicular membranes  
2006  Tarpey  et al. 2006 
RPL10  Ribosomal protein 
L10 
Assembly of large 
ribosomal subunit, 
protein synthesis 
2005  Klauck et al. 2006 
CUL4B  Cullin 4B  E3 ubiquitin ligase, 
proteolysis of DNA 
replication regulator 
2007  Tarpey  et al. 2007 
ZDHHC9  Zinc finger, DHHC-
type containing 9 
Kinase, post-
translational 
modification 
2007  Raymond et al.  2007 
BRWD3  Bromodomain and 
WD repeat domain 
containing 3 
Intracellular signaling 
pathways affecting 
cell proliferation 
2007  Field et al. 2007 
UPF3B  UPF3 regulator of 
nonsense transcripts 
homolog B 
Nucleotide binding, 
nonsense-mediated 
mRNA decay 
2007  Tarpey  et al. 2007 
GRIA3  Glutamine receptor, 
ionotrophic, AMPA3 
Signal transduction, 
excitatory 
neurotransmitter 
receptor 
2007  Wu et al. 2007 
HUWE1  HECT, UBA-and 
WWE-domain 
containing 1 
E3 ubiquitin ligase, 
p53 associated 
regulation of 
neuronal cell cycle 
2008  Froyen  et al. 2008 
SLC9A6  Solute carrier family 
9 (sodium-hydrogen 
exchanger) 
Sodium ion transport, 
pH regulation 
2008  Gilfillan et al. 2008 
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Gene 
Symbol 
Gene Name  Protein Function  Years 
 Found 
References 
MAGT1  Magnesium 
transporter 1 
N-Glycosylation of 
neuronal cell 
adhesion molecules 
2008  Molinari et al. 2008 
ZNF711  Zinc finger protein 
711 
DNA replication  2009  Molinari  et al. 2008 
CASK  Calcium/calmodulin-
dependent serine 
protein kinase 
Kinase, post-
translational 
modification 
2009  Tarpey et al. 2009 
SYP  Synaptophysin  Synaptic vesicle 
maturation and 
membrane 
organization 
2009  Tarpey et al. 2009 
(adopted from Gecz, 2009) 
 
II.2.4.2. Positional Candidate Gene Analysis 
A purely positional approach is often inefficient because candidate regions 
identified by positional cloning usually contain dozens of genes, which will be 
time-consuming  and  labour-consuming  to  screen  them  all.  This  matter  can  be 
resolved  by  combining  both  positional  and  non  positional  information  in  a 
positional candidate gene approach. This method uses mutation analysis of the 
most  promising  functional  candidate  genes  encompassed  by  linkage  intervals 
(Strachan and Read, 1999). Several genes that have been found by this approach 
are: GDI1, PAK3, and RSK2 (Mulley, 2008).  This method brings advantages for 
being effective and economical method for direct gene discovery. However, the 
practicability of this approach is limited by its reliance on prior knowledge about 
the known or presumed biology of the phenotype under investigation, necessity of 
discrete  phenotypic  differences,  and  also  necessity  of  highly  subjective  in  the 
process of choosing specific candidates from numbers of potential possibilities. 
(Zhu and Zhao, 2007). 
Nowadays,  the  technology  development  emerges  several  bioinformatic 
tools that could help in candidate gene prioritization. This tools use concept of 
data-fusion  (Figure  4)  which  prioritizing  candidate  genes  based  on  combined 
information from many sources, including converging actual experimental data, 
web database-based resources (including literature-based resources and biological 
ontology  resources)  or  the  theoretical  assembling  of  molecular  features  or 18 
 
molecular  interaction  principles,  e.g.,  gene  structure  variation,  homologs, 
orthologs,  SNPs  data,  protein-DNA  interactions,  protein-protein  interactions 
(interactome), molecular module, pathway and gene regulatory network (Aerts et 
al.  2006).    Several  bioinformatic  tools  that  use  data-fusion  for  prioritizing 
candidate genes are Endeavour  (Aerts et al. 2006) and ToppGene (Chen, 2007).   
 
 
Figure 4. Concept of data fusion (adopted from KU Leuven, 2010). 
 
Both  Endeavour  and  ToppGene  use  the  training  genes,  genes  already 
known to be involved in the process under study, as model. Then, the model is 
used to score the candidate genes based on the similarity and rank them according 
to  their  score  (Chen,  2007).  The  basic  difference  of  those  software  is  that 
Endeavour use Blast, cis-element and transcriptional motifs in sequence features 
and annotation, while ToppGene not. The other difference is that ToppGene use 
mouse phenotype in the annotation, and PubMed ID for literature information, 
while Endeavour not using mouse phenotype and use keywords in abstract for 
literature data (Table 3; Chen, 2007).  In 2008, Endeavour extend the framework 
to several model organism, so it can be performed for M. musculus, R. norvegicus 19 
 
and  C.  elegans,  and  also  developing  the  versions  for  D.  rerio  and  D. 
Melanogaster (Tranchevent et al., 2008). However, it is important to remember 
that prioritizing candidate genes is only worked for syndromic MR. 
 
Table 3. Comparisson between Endeavour and ToppGene  
Feature type  ENDEAVOUR  ToppGene 
Sequence Features & 
Annotations 
Blast 
cis-element 
Transcriptional motifs 
Not used 
Gene Annotations  Gene Ontology 
 
Gene Ontology  
Mouse Phenotype 
Transcript Features  Gene expression 
EST expression 
Gene expression 
Protein Features  Protein domains 
Protein interactions 
Pathways 
Protein domains 
Protein interactions 
Pathways 
Literature  Keywords in abstracts  Co-citation (PMIDs) 
(adopted from Chen et al., 2007) 
 
II.2.4.3. Mutation analysis of known gene  
XLMR  is  a  clinically  complex  and  genetically  heterogeneous  disorder 
arising from many mutations along the X chromosome. Lately, two large studies 
by  de  Brouwer  et  al  and  Raymond  et  al  showing  the  contribution  of  point 
mutations to XLMR. Brouwer et al in 2007 screened 90 known and candidate 
XLMR  genes  in  a  cohort  of  600  families  of  varying  size  and  identified    73 
mutations in 21 genes, resolving 42% of the families (de Brouwer et al., 2007).  
Fascinatingly,  this study also showed that there was no significant difference 
between the proportion of resolved large families with LOD >2.0 and smaller 
families with LOD <2.0. Tarpey et al in 2009 screened the coding regions of 718 
genes in probands from 208 families and detected 1,858 different coding sequence 
variants (Tarpey et al., 2009). In this study, the proportion of  resolved brother 
pairs and larger families were quite similar, 21% versus 23%, which indicating 
that a considerable proportion of affected brother pairs might result from X-linked 
mutations.  
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II.2.4.4. Array technology 
This technology appeared seven years ago, when  Veltman et al described 
microarray-based copy number analysis of all human telomeres in patients with 
mental retardation (Veltman et al., 2002). Later on, microarrays have developed 
and  target not only the telomeres, but even  entire genome at varying resolution 
levels (Menten et al., 2006).  In the beginning, the array technology used clone-
based  genomic  microarrays  was  only  available  to  researchers  with  dedicated 
microarray  facilities.  Nowadays,  these  microarrays  have  been  replaced  by 
commercially  available  microarrays  using  oligonucleotide  probes  with  higher 
genome  coverage  that  can  easily  be  put  into  practice  in  clinical  diagnostic 
laboratories  (Koolen  et  al.,  2009).  Increasing  resolution  of  the  different  array 
platforms  open  up the possibility  to  detect  smaller  and  smaller  genomic  copy 
number  variations  (CNVs)    (Vissers et al.,2009).  There  were  several  different 
chromosome X specific DNA microarrays  developed and applied for screening of 
XLMR families in search for new causative mutations (Bashiardes et al., 2009). 
The first chromosome X-specific array CGH study using tiling resolution BAC 
array gave causal hit in 3 of 40 patients with nonspecifix-XLMR (Lugtenberg et 
al.,2006a), later followed by identification of novel nonspecific XLMR gene by 
this approach (Lugtenberg et al, 2006b), indicating that this method is useful in 
XLMR. However, the array practice is still hampered by the high cost needed and 
challenging interpretation of the CNV results. Nowadays, 2.7M array is available, 
With  unbiased,  whole-genome  coverage  and  the  density  of  2.7  million  copy 
number  markers,  this  array  enables  detection  of  the  smallest  submicroscopic 
aberrations,  including  those  that  would  have  been  missed  with  classical  array 
techniques (Affymetrix). 
 
II.2.4.5. Next generation sequencing 
The  newest  advances  in  DNA  sequencing  technologies,  called  next-
generation sequencing (NGS) technologies, are now enabling the comprehensive 
analysis  of  whole  genomes,  transcriptomes  and  interactomes.  This  method 
capable of detecting both single base mutations and structural variation (Visser et 21 
 
al., 2009), with capability of reading 400 K—4 M sequences compared with the 
traditional 96 capillary, and reading length from 25 to 450 basepairs, depending 
on the platform (Mardis, 2008). In shotgun sequencing, the genome is cut up into 
smaller  fragments  of  DNA  which  can  be  massively  sequenced  in  parallel. 
Subsequently, the sequenced fragments are assembled into contigs based on the 
overlap  in  the  sequence  reads  or,  alternatively,  aligned    and  compared  to  a 
reference genome which will bring to disease-gene identification. This promising 
method,  however,  still  limited  by  its  high  cost.    Clinical  and  biological 
interpretation  the  variants  resulted  from  this  method  will  require  large 
international and multidisciplinary collaborative efforts (Visser et al., 2009) 
  
II.3. X-Chromosome Linkage Analysis 
Before  researchers  could  elucidate  and  finally  sequence  the  gene 
responsible for a disease, it must be first mapped, located in the Genome. Genetic 
linkage  analysis  plays  role  in  identification  regions  of  the  genome  containing 
genes  (locus)  that  predispose  to  disease  by  use  of  observations  of  related 
individuals  (Teare  and  Barret,  2005).  This  method  works  using  short  tandem 
repeat (STR)-markers or microsatellite, a well-characterized regions of DNA that  
consist of multiple repeats of a short sequence (typically 2–8 bp) and highly show 
genetic variation (polymorphism) in nature (Weber, 1990). Researcher are looking 
for  a marker  that  is consistently present  in those that are affected,  and is  not 
present  in  non-affected  relatives,  assuming  that  a  causative  genetic  variant  is 
likely to lie close to that marker (Burton et al. 2005).  Linkage analysis work on 
the  principle  of  cosegregation  of  stretches  of  DNA  in  families  rearranged  by 
recombination events in meiosis. The probability of recombination between two 
loci at meiosis is called recombination fraction (Ө), which can be utilized as a 
stochastic measure for the genetic distance between two genes (Massanet, 2009). 
The further apart two loci are from each other on a chromosome, the greater the 
probability  is  that  a  recombination  will  occur  between  them(hypothesis  null 
assumes  no linkage, or  Ө=0.5) (Teare and Barret, 2005). Two loci  segregate 
together  more  often  if  they  are  located  close  enough  together  on  the  same 22 
 
chromosome (in other words the chance of recombination is less than 50%, or 
alternative hypothesis assumes linkage exists (Ө<1/2)) (Burton et al. 2005). The 
expected  numbers  of  recombination  occurring  between  two  loci  on  a  single 
chromatid during meiosis is called genetic map distance (in units of Morgans) 
(Teare and Barret, 2005). Linkage is described in linkage interval and scored in 
logarithm  of  the  odds  (LOD)  score,  a  function  of  the  recombination  which 
indicates how much higher the likelihood of the data is under linkage than under 
the absence of linkage (Massanet, 2009). 
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Morton (1955) proposed a critical value of LOD score=2 for significant linkage in 
X-linked locus (Morton, 1955).  Linkage can be excluded from the region if the 
LOD score is below -2. This approach  is called exclusion mapping (Massanet, 
2009).  In mental retardation, linkage analysis is often used as first stage to narrow 
down  region  of  interest  into  linkage  interval  in  effort  to  find    evidence  of 
containing a disease gene (Teare and Barret, 2005).  Candidate gene present in the 
linkage interval can be used as a target of sequencing to find the disease causing 
genes (Lugtenberg et al., 2006). 
  
II.4. X-Chromosome Inactivation 
X-chromosome  inactivation  (XCI)  is  described  as  the  transcriptional 
silencing of one of the two X-chromosomes in female mammalians (Orstavik, 
2009).  Males  have  one  copy  whereas  females  have  two  copies  of  the  X 
chromosome, and this potential dosage difference from the two X-chromosomes 
in females is equalized by inactivating one X in humans and other mammals at 1N 
(Agrelo  and  Wutz,  2009;  Nora  and  Heard,  2009).  As  the  result,  females  are 
mosaics for two cell populations cells with either the paternal or the maternal X in 
the  active  form  (Kristiansen  et  al.,  2005).  This  mechanism    occurs  in  early 
embryonic  life  at  the  preimplantation  stage  following  early  whole-genome 
activation, and is stochastic and permanent for all descendants of a cell (Berg et 
al., 2009).  This event is orchestrated by the X-inactivation center (Xic) located on 23 
 
the  X-chromosome  (Royce-Tolland  and  Panning,  2008).    The  silencing 
mechanism of the X-chromosome is a complex mechanism involving interplay 
between  noncoding  transcripts  such  as  Xist,  chromatin  modifiers,  and  factors 
involved  in  nuclear  organization  (Chow  and  Heard,  2009).  Most  of  the  X-
chromosome,  with  exception  of  pseudoautosomal  regions  at  Xpter  and  Xqter, 
participates in the inactivation (Miller et al., 1995). 
Generally, X-chromosome inactivation is a random process, which result 
in 50% of cells expressing the paternal and the remaining 50% expressing the 
maternal genes (Migeon, 2007). Once this ratio is established,  it remains fixed for 
all descendants of a particular cell.  This random inactivation is altered in the 
presence  of  certain  gene  mutations  and  genomic  alternations,  where  the 
chromosome bearing the mutated gene or region is preferentially inactivated. If 
there is a marked deviation from this 50:50 ratio, then it will be called skewing of 
XCI,  arbitrarily defined as preferential inactivation of either the maternally or 
paternally inherited X-chromosome in 30:70 or more of cells (Plenge et al., 2002). 
A  ratio  of  X-inactivation  of  >90:10  is  defined  as  marked  skewing  of  X-
inactivation (Stevenson and Schwartz, 2009). 
In  XLMR,  skewed  X-chromosome  inactivation  is  often  observed  in 
phenotypically normal females who carry the mutant gene. This phenomena is 
presumed to work as selection against cells that express the mutant allele during 
early development and the degree of skewing can vary between different tissues 
(Muers, 2007). Previous studies of families with XLMR indicated skewed XCI in 
all carriers in three of 19 (Raynaud et al., 2000) and four of 20 families (Plenge et 
al., 2002). Skewed X-chromosome inactivation is more or less consistently seen in 
carriers  of  genomic  duplications  and  X-linked  alpha-thalassemia  mental 
retardation syndrome (ATRX) mutations. Also, marked skewing of X-inactivation 
is  less  consistently  present  in  carriers  of  other  XLID  disorders  (Plenge  et 
al.,2002). So, skewed XCI in the mother of an affected male may indicate the 
presence of  XLMR.  However, random XCI does not exclude the possibility of an 
X-linked disorder (Orstavik et al., 2009).   
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II.5. Genetic Counselling 
The implication of a genetic diagnosis on an individual will also affect the 
entire family.  Thus, genetic counselling is crucial  in genetic condition. Genetic 
counseling is described as “... the process of helping people understand and adapt 
to the medical, psychological and familial implications of genetic contributions to 
disease,”. (National Society of Genetic Counselors’ Definition Task Force et al. 
2006). In this process, genetic counselors play pivotal roles in risk assessment and 
patient counseling, consultation and case management, and education for patients 
and  providers  (O’Daniel,  2009).  Risk  assessment  is  important  for  prospective 
parents,  especially  couples  who  already  have  a  child  with  mental  retardation. 
Parents  are  keen  to  know  the  risk  of  their  next  child  being  affected.  This 
information may help them make informed decisions about having the next child. 
(WHO, 2010).  
Despite  the  importance  and  advantages  of  genetic  counselling,  many 
children  who  should  be  receiving  genetic
 counseling  and  testing  often  do  not 
receive  all  of  the  services
 they  require  (Wang  and  Watts,  2007).  Data  from 
American Academy of Paediatric have indicated that families of children with 
mental  retardation  perceive  significantly  higher  need  for  genetic  counselling 
compared  to  other  children  with  special  need.  Data  from  2005–2006  National 
Survey of Children With Special Health Care Needs also showed that access to 
genetic counselling services is affected by several barriers: the lack of a medical 
home, the lack of insurance, low family income and low education attainment 
(McGrath et al., 2009).  There are also several factors influencing transmission of 
genetic  counselling  information  inside  family  members.  First-degree  family 
members  are  more  frequently  informed  compared  to  second-  or  third-degree 
family member (Claes et al., 2003). Gender is also play role in this process, as 
women are more likely to communicate (d’Agincourt-Canning, 2001). Intrafamily 
mode of communication and emotional bond, mode of inheritance of the genetic 
condition, positive family history and the perception ofthe ability to act on the 
genetic information are also affecting the transmission of information (Forrest et 
al., 2008).   25 
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CHAPTER III 
  RESEARCH METHOD    
 
III.1. Research Aspect 
III.1. 1. Research Field 
This research was in the field of Molecular Genetics, intercorrelated with 
Clinical Genetics.   
 
III.1.2. Research Location 
Indonesian families from patients and several special schools for intellectual 
disabilited people in Semarang and patients were collected and examined. 
Conventional cytogenetic analysis for Indonesian patients was carried out in 
the  Molecular  and  Cytogenetic  Laboratory  of  Center  of  Biomedical 
Research,  Faculty  of  Medicine  Diponegoro  University  Semarang.  Dutch 
families were collected from available DNA from the Radboud University 
Nijmegen Medical Center (RUNMC), the Netherlands. DNA analysis for 
Fragile-X  syndrome,  linkage  analysis,  X-chromosome  inactivation  status 
and  sequencing  analysis  of  candidate  gene  were  performed  in  the 
department  of  Human  Genetics,  Radboud  University  Nijmegen  Medical 
Center (RUNMC), the Netherlands. 
 
III.1.3. Research Period 
Sample collection ,conventional cytogenetic analysis and DNA extraction: 6 
months. Molecular analysis: 12 months.  
 
III.1.4. Research Design 
This was a descriptive study. 
 
III.1.5. Variables 
- Dependent variable: X-linked mental retardation 
Scale: Nominal 27 
 
- Independent variable: Cytogenetic and molecular result 
Scale: Nominal 
 
III.1.6. Operational Definition 
-  Phenotype : all clinical features 
-  Genotype : all genetic defects found in molecular analysis 
-  Mental Retardation: According to American Association on Intellectual 
Developmental Disabilities : 
-  IQ<70 
-  concomitant limitations in two or more areas of adaptive skills 
-  Onset before the age of 18  
-  X-Linked Mental Retardation: Families with a pedigree suggestive of 
X-linked inheritance: 
-  at  least  two  males  with  mental  retardation  with  or  without 
additional clinical findings for the Indonesian families 
-  at least two males with syndromic mental retardation for the Dutch 
families 
-  predominant sparing of carrier females 
-  no evidence of male-to-male transmission of mental retardation 
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III.1.7. Research Protocol 
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III.2 . Method 
III.2.1. Population 
Families with multiple individuals of mentally retarded were included in 
this study. Families originated from Indonesia and the Netherlands.  
 
III.2.2. Samples 
Samples were collected from family members of the Indonesian and Dutch 
families which showing X-linked inheritance from the pedigree.   
 
III.2.2.1 Inclusion Criteria 
-  Families with a pedigree suggestive of X-linked inheritance:  
*  at least two males with mental retardation with or without 
additional clinical findings  
*  predominant sparing of carrier females 
*  no  evidence  of  male-to-male  transmission  of  mental 
retardation.   
-  DNA  available  from  two  or  more  affected  family  members  and 
parents. 
-  written informed consent obtained 
 
III.2.2.2 Exclusion Criteria 
-  X-linked families with clinical suspicion of known MR syndromes, 
for example: Down Syndrome. 
 
III.2.2.3. Clinical Examination 
Indonesian  families:  patients  was  clinically  examined,  according  to  the 
RUNMC form, by a medical doctor from  CEBIOR Semarang. Clinical 
photograph was taken from the affected children. 
Dutch families: patients were clinically examined by a clinical geneticist 
form the department of Human Genetics, RUNMC, the Netherlands. 
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III.2.2.4. Sample Collection 
Indonesian  families:  For  all  patients,  siblings  and  parents,  5  mL 
heparinized blood was obtained for conventional cytogenetics  and 5-10 
mL EDTA blood was obtained for DNA isolation.  
Dutch families: for all patients heparinized blood was obtained for EBV 
transformation of lymphocytes and EDTA blood was obtained for DNA 
isolation. 
 
III.2.2.5 Minimum samples required 
No minimal number of samples required, as this study is a molecular study 
(not a population study). 
 
III.3. Work-flow 
III.3.1. General 
Figure 5 illustrates general workflow of this research. The first step was a 
thorough  clinical  work-up,  which  could  exclude  acquired  factor  from 
anamnesis.  Pedigree  of  the  family  was  drawn  to  describe  the  mode  of 
inheritance in the family. Physical examination with special attention on 
clinical dysmorphologic examination was performed as described above to 
exclude  known  syndrome  for  example  Down  Syndrome  (Appendix  1). 
Blood samples was taken from all families for cytogenetic preparation and 
DNA isolation.  Conventional cytogenetic analysis was performed in all 
families to exclude gross chromosomal abnormalities and also by paying 
special attention  to fragile-site, followed by analysis of CGG repeat  to 
exclude  Fragile-X.  Linkage  analysis  was  conducted  with  highly 
polymorphic STR-markers evenly spread over the X-chromosome to find 
the  linkage  interval.  An  FMR1  X-chromosome  inactivation  assay  was 
performed to determine the X-inactivation status of carrier females from 
all families. Females that were uninformative for FMR1 were analyzed for 
X-chromosome  inactivation  status  by  using  the  CAG  repeat  of  AR. 
Promising candidate genes were selected in linkage intervals on the X-31 
 
chromosome using bioinformatic tools (ToppGene  and Endeavour; Chen 
et al, 2007; Tranchevent et al, 2008) and by manual selection based on the 
expression in  brain/neuronal  tissues,  homology  with  known  MR  genes, 
involvement in the same protein network as already known MR genes, and 
X-inactivation status of the genes. Mutation analysis of the most promising 
candidate  genes  was  performed.  2.7M  array  was  performed  on  one 
affected  of  each  syndromic  XLMR  families.  More  details  about 
chromosomal  preparation  procedures,  DNA  Isolation,  FMR1  gene 
amplification,  X-Chromosomal  Linkage  Analysis,  X-Chromosome 
inactivation analysis and candidate gene selection procedures can be found 
in the appendix section. 
 
III.4 Collected Data   
III.4.1 Primary Data: 
MR patients including personal data: date of birth and pedigree.  
 
III.4.2. Secondary Data: 
Medical records from special schools and medical record from the RUNMC. 
 
III.5 Data analysis 
Data  was  analyzed  with  the  descriptive  method  and  presented  in  tables  and 
graphics. 
 
III.6. Ethical Implication 
-  This  research  involved  affected  person  which  unable  to  give  consent. 
Informed consent will be obtained from the parents. Parents were given 
right to decline their involvement in this research. Informed consent form 
is attached in the Appendix 1. 
-  All  data  including  patients  and family  identity,  clinical,  and  laboratory 
data was confidential.  
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Figure 5.  Multiple steps in linkage analysis 
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CHAPTER IV  
RESULTS AND DISCUSSION 
 
IV.1 Clinical Findings  
Clinical  examination  was  performed  in  Indonesian  samples  based  on 
standarized  protocols from  Radboud  University  of  Nijmegen  (Appendix  1).  A 
detailed description of antropometry parameters and dysmorphisms also described 
in  the  form.  In  four  families,  the  pedigree  and  clinical  examinations  were 
compatible  with  syndromic  XLMR  (table  3).  Six  families  presented  with  non 
syndromic XLMR.  Main clinical features in the syndromic XLMR families were 
hydrocephalus  (family  P03-0452  and  13753/HC),  hypomyelination  (family 
W092-053) and overgrowth features (family DF27004) (table 4). 
 
Table 4 . Summary of Dysmorphological Features 
Family 
Number 
Indonesian
/Dutch 
Syndromic/ 
Non Syndromic 
Dysmorphological Features 
P03-0452  Dutch  Syndromic  mental retardation, congenital 
hydrocephalus, short stature, obesity, 
hypogonadism 
13753/HC  Dutch  Syndromic  mental retardation, congenital 
hydrocephalus 
W92-053  Dutch  Syndromic  mental retardation, blindness, 
convulsion, spasticity, early death, 
hypomyelination 
DF27004  Dutch  Syndromic  Mental retardation, macrocephaly, 
hepatomegaly, kidney enlargement 
W09-0071  Indonesian  Non Syndromic  mental retardation, sandal gap, flat 
foot, high arched palate, tappering 
pad, short third toe 
W09-0072  Indonesian  Non Syndromic  mental retardation, prominent ear, 
long face, broad nasal bridge 
W09-0074  Indonesian  Non Syndromic  mental retardation, prominent ear, 
macroorchidism 
W09-0078  Indonesian  Non Syndromic  Mental retardation, long face, heavy 
eyebrow, prominent ears, sandal gap, 
pes planus 
W08-2152  Dutch  Non Syndromic  Mental retardation, autism, epilepsy, 
long narrow  face, deep set eyes, 
high nasal bridge, macroorchidism, 
short fifth metatarsal, long finger and 
toes 34 
 
Family 
Number 
Indonesian
/Dutch 
Syndromic/ 
Non Syndromic 
Dysmorphological Features 
W07-604  Dutch  Non Syndromic  Mild to moderate mental retardation, 
behavioral problems 
 
IV.2 Conventional Cytogenetic analysis 
Conventional cytogenetic analysis was performed in all Indonesian and 
Dutch  samples.  None  of  the  affected  probands  showed  any  macroscopic 
choromosomal abnormalities. 
 
IV.3 Fragile-X exclusion test 
PCR analysis of the CGG repeat in the promoter region of FMR1 was 
performed in all Indonesian samples. None of the affected probands showed any 
CGG repeat more than 55 (Table 5). In all Dutch families Fragile-X syndrome 
was already excluded previously.  
 
Table 5. CGG repeat sizes in subject screened by FMR1 analysis 
Family 
Number 
Patient 
Number 
Gender  CGG Repeat  Remarks 
W09-0071  50156  Male  28 repeat  Normal 
W09-0072  WB70  Male  36 repeat  Normal 
W09-0072  35/NK/08  Male  29 repeat  Normal 
W09-0072  32/NK/08  Female  29 repeat 
32 repeat 
Normal 
 
 
IV.4 Linkage Analysis 
  Linkage  analysis  was  performed  in  eight  families.  Linkage  analysis  in 
family  W92-053  and  W07-604  had  already  performed  in  other  center  before. 
Main interval size was varied from 8 Mb to 121 Mb (Table 6). 
 
Table 6. Linkage analysis result in all families 
Family 
Number 
Indonesian
/Dutch 
Interval  Interval 
Size 
LOD  
Score 
P03-0452  Dutch  Xq22.2-Xq27.2 
Xq27.2-Xq28 
37 Mb 
12 Mb 
0.2 
13753/HC  Dutch  Xp21.1-Xq28  121 Mb  0.6 
W92-053  Dutch  Xp11.3-q12  20 Mb  3.30 35 
 
Family 
Number 
Indonesian
/Dutch 
Interval  Interval 
Size 
LOD 
Score 
DF27004  Dutch  Xp22.2-Xq21.32 
Xq26.3-Xq28 
79 Mb 
17 Mb 
1.62 
W09-0071  Indonesian  Xp22.2-Xp22.11 
Xp11.4-Xq25  
 8 Mb  
81 Mb  
0.75 
W09-0072  Indonesian  Xp22.2-Xp11.3   32 Mb   0.91 
W09-0074  Indonesian  Xp22.2-xp11.3 
Xq25-Xq28 
32 Mb  
31 Mb  
0.3 
W09-0078  Indonesian  Xq23-q27.3   45 Mb   1.39 
W08-2152  Dutch  Xq25-Xq28   31 Mb   1.36 
W07-604  Dutch  Xp21.1-Xp22.2  28 Mb   
 
IV.5 X-Chromosome Inactivation Analysis  
XCI status was found to be informative in  13 of the  18 female carriers for 
analysis of the CGG repeat in the promoter region of FMR1. Five females carriers 
that were uninformative for FMR1 then were examined by analysis of the CAG 
repeat in the promoter region of AR.  Skewed XCI (> 80% skewing) was observed 
in four (patient 50165 from family W09-0072, patient 51677 from family W08-
2152, patient 29301 from family P03-0452, and patient 3485 from family W92-
053; Table 7) of the eighteen female carriers.   
  
Table 7.  XCI status for Females 
Family 
Number 
Sample 
Number 
% XCI  Remarks 
    FMR1  AR   
W09-0071  50157  Uninformative  58%  No Skewing  
  50161  Uninformative  46%  No Skewing 
W09-0072  50165  100%    Skewing 
  50169  59%    No Skewing 
  50170  42%    No Skewing 
  50172  Uninformative  64%  No Skewing 
W09-0074  50174  56%    No Skewing 
W09-0078  50207  36%    No Skewing 
  50198  39%    No Skewing 
  50209  Uninformative  74%  No Skewing 
W08-2152  51677  100%    Skewing 
W07-604  42721  41%    No Skewing 
P03-0452  29301  Uninformative  0%  Skewing 
13753/HC  26744  65%    No Skewing 
  27003  54%    No Skewing 36 
 
Family 
Number 
Sample 
Number 
% XCI 
  
 Remarks 
    FMR1  AR   
W92-053  3485  100%    Skewing 
DF27004  4992  41%    No Skewing 
  4984  28%    No Skewing 
 
IV.6 Mutation analysis in Candidate Genes 
Due to specifical clinical features, candidate gene can only be selected in four 
syndromic XLMR families. Mutation analysis was performed in candidate genes 
and revealed no mutation (Table 8). 
 
Table 8. Candidate genes sequencing  
Family  Patient  Candidate Gene  Sequencing Relust 
W92-053  3485  HSD17B10  No mutation 
    SYP  No mutation 
    SYN1  No mutation 
    UBQLN2  No mutation 
    ARHGEF9  No mutation 
P03-0452  28558  SLITRK2  No mutation 
    SLITRK4  No mutation 
13753/HC  26857  SLITRK2  No mutation 
    SLITRK4  No mutation 
DF27004  33431  GPC3  No mutation 
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IV.7.  Results and discussion for each family 
Family W92-053 (XLMR and hypomyelination family) 
Clinical Examination 
Dutch family W92-053 has been reported before by Hamel et al. in 1999 (Hamel 
et al., 1999).  From the history, it was described that for  IV.5, IV.7, and IV.8, 
pregnancy and delivery had been uneventful and all were born with bilateral pes 
calcaneovalgus. Since the age of 3 months, the onset was started with gradual loss 
of vision, spastic tetraplegia and scoliosis, convulsions, secondary microcephaly, 
unexplained,  febrile  episodes,  severe  mental  retardation,  and  failure  to  thrive. 
Hearing was normal. They never sat, crawled, nor spoke. Proband IV.5 died at the 
age of 29 months during a febrile episode. Proband IV.7 died at the age of 161⁄2 
months from aspiration pneumonia. Proband IV.8 died at the age of 26 months of 
aspiration  pneumonia.  Obligate  and  possible  female  carrier  showed  no 
abnormality. 
Laboratory Analysis 
Ophthalmological  examination  showed  pale  fundi  in  patient  IV.5.  The 
EEG showed an epileptic focus in the left frontotemporal region. The skeletal age 
was retarded as well. In patient IV.8, ophthalmological examination showed pale 
fundi  as  well,  whereas  the  EMG  was  normal.  Metabolic  analysis  showed  no 
abnormalities (1971). Lysosomal enzymes (in 1971) were normal.  
Patients IV.7 and IV.8 showed small brain for age, thin gyri, hypomyelination 
(Hamel et al., 1999). Patient IV.7 showed delicate optic nerves. Slightly enlarged 
lateral ventricles were found in family member IV.8.   
Genetic Analysis 
Conventional  cytogenetic  analysis  showed  no  gross  chromosomal 
aberration in IV.5, IV.7, and IV.8 (Hamel et al., 1999). Linkage analysis pointed 
to a 20 Mb linkage interval at Xp11.3-q12, with maximum lod score of 3.30 at 
θ=0.0  in marker DXS1204, with DXS337 and PGK1P1 as  flanking markers 
(Hamel et al., 1999).  Haplotypes in the family member are shown in Figure 6. X-
Chromosome  inactivation  analysis  on  III.9  showed  skewing  X-chromosome 
inactivation. 38 
 
Candidate Gene Selection 
We  checked  the  genes  contents  in  the  linkage  interval  using  UCSC 
Genome  Browser.  There  were  215  genes  in  the  20  Mb  linkage  interval.  We 
performed candidate gene selection using manual selection and ENDEAVOUR, a 
bioinformatic tool that can be used to prioritize candidate genes.  
We used 128 genes associated with demyelination and 14 genes associated 
with hypomyelination from NCBI Entrez Gene as a training set, and 215 genes in 
the  linkage  interval  as  test  set  for  candidate  gene  prioritization  with 
ENDEAVOUR (Fig 7).  We did not choose other top genes such as AR, UXT, 
ALAS2 for candidate genes because previous reports showed that mutation found 
in those genes were not associated with mental retardation features. Instead,we 
selecteded HSD17B10, SYP, SYN1, UBQLN2 and ARHGEF9 as candidate genes.  
 
 
Figure  6.  Haplotypes  within  family  W92-053  as  described  by  Hamel  et  al 
(adopted from Hamel et al., 1999). The cosegregating haplotype has been marked 
by a black bar. Filled symbols represent male patients with MR. 
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HSD17B10  encodes  17-beta-hydroxysteroid  dehydrogenase  X,  a 
multifunctional mitochondrial enzyme that acts on a wide spectrum of substrates. 
Mutation in HSD17B10 associated with HSD10 deficiency, which is characterized 
by  normal  or  mildly  delayed  development  in  the  first  months  or  year  of  life, 
followed by regression of previously acquired motor and mental skills (Korman, 
2006). Additional clinical features include myoclonic or other seizures, hypotonia, 
optic atrophy, pigmentary or non-pigmentary retinopathy, sensorineural deafness, 
ataxia,  dystonia,  choreoathetosis,  spastic  di-/tetra-plegia,  cardiomyopathy 
frontotemporal or frontoparietal atrophy with enlarged ventricles parieto-occipital 
periventricular white matter and mild dysmorphism (Olpin et al.,2002; Sutton et 
al.,2003;  Poll  The  et  al.,  2004;  Perez-Cerda  et  al.,  2005).  SYP  encodes 
synaptophysin, an integral membrane protein of small synaptic vesicles which are 
found  in  brain  and  endocrine  cells.  Previous  reported  mutation  in  SYP  were 
associated with X-linked mental retardation and epilepsy (Tarpey et al., 2009). 
SYN1  encodes  synapsin  I,  a  neuronal  phosphoprotein  associated  with  the 
membranes of small synaptic vesicles which may have a role in the regulation of 
neurotransmitter release. Previous reported mutation on this gene were associated 
with mental retardation, behaviour problems, and epilepsy (Garcia et al., 2004). 
UBQLN2  encodes  an  ubiquitin-like  protein  (ubiquilin),  which  are  thought  to 
functionally link the ubiquitination machinery to the proteasome to affect in vivo 
protein degradation. ARHGEF9 is a member family of Rho-like GTPases that act 
as  key regulators  of the actin cytoskeleton and are involved in cell signaling. 
ARHGEF9 disruption is associated with X linked mental retardation and sensory 
hyperarousal (Marco et al., 2008). Direct DNA sequencing of HSD17B10, SYP, 
SYN1, UBQLN2 and ARGHEF9 in patient III.9 revealed no mutation.   
Genetic Counselling 
No candidate gene mutation was found in this family. However, linkage 
analysis  revealed  that  this  family  shared  clear  X-linked  inheritance    and  that 
patient  II.1,  II.2,  III.9,  III.20  (female)  and  IV.7  (male)  shared  similar  risk 
haplotype which can affect their children. The rest of living male did not share 40 
 
risk haplotype, thus there are no risk of developing this disorders in their next 
generation. This finding can be used for genetic counselling purpose 
Discussion 
We analysed HSD17B10, SYP, SYN1, UBQLN2 and ARGHEF9 in patient 
III.9  but  found  no  mutation.  Previously,  there  were  already  several  XLMR 
syndrome  associated  with  neurological  features  and  early  death  according  to 
Online Mendelian Inheritance in Man (OMIM; table 9). However, none of the 
conditions linked to the pericentromeric region.  
 
 
Figure 7. Top 25 candidate genes according to candidate gene prioritization with 
ENDEAVOUR for family W92-053. 
 
The clinical presentations of patients in family W92-053 resemble HSD10 
deficiency  (formerly  called  2-methyl-3-hydroxybutyryl-CoA  dehydrogenase 
(MHBD) deficiency), which  is predominantly characterized by neurodegenerative 
phenotype. In HSD10 deficiency, there is an increase in excretion of 2-methyl-3-
hydroxybutyric  acid  (2M3HBA)  and  tiglylglycine  (TG)  and  absence  of  2-
methylacetoacetic acid (2MAA) (Korman, 2006). However, in family W92-053, 41 
 
there  were  no  metabolic  abnormalities  found,    considering  the  time  of 
examination in 1971.    
 
Table 9. XLMR syndromes associated with neurological features and early death   
Name  MIM  Locus 
Lubs X-linked mental retardation syndrome; MRXSL  300260  Xq28 
Spinal muscular atrophy, X-linked 2; SMAX2  301830  Xp11.23 
Adrenomyodystrophy  300270  - 
Adrenoleukodystrophy; ALD  300100  Xq28 
 Rett Syndrome   312750   Xq28 
Arts Syndrome  301835  Xq22-q24, 
Xq21.2-q24 
Spastic Paraplegia 2 (SPG2)  312920  Xq22 
Cantu  308830  - 
Gustavson Syndrome  309555  Xq26 
Mental retardation-hypotonic facies syndrome, X-linked, 1    309580  Xq13 
HSAS  308840  Xq28 
Microphthalmia, syndromic 1    309800  Xq27-q28 
Lowe Syndrome  309000  Xq26.1 
Lesch-Nyhan Syndrome  300322  Xq26-q27.2 
Menkes Syndrome  309400  Xq12-q13 
Paiene-Seemanova Syndrome  311400  - 
Pelizaeus-Merzbacher Disease; PMD    312080  Xq22 
Pyruvate decarboxylase deficiency  312170  Xp22.2-p22.1 
Spinocerebellar ataxia, X-linked 3    301790  - 
VACTERL with hydrocephalus  314390  - 
Wittwer  300421   Xp22.3 
Hoyeraal-Hreidarsson Syndrome   300240   Xq28 
Mucopolysaccharidosis type II    309900  Xq28 
Allan-Herndon-Dudley Syndrome    300523  Xq13.2 
 
In  genetic  basis,  HSD10  deficiency  is  associated  with  mutation  in 
HSD17B10  (formerly  the  HADH2)  which  encodes  hydroxysteroid  (17β) 
dehydrogenase  10  (HSD10)  (Korman,  2006).  HSD10  plays  role  as  a 
mitochondrial multifunctional enzyme which catalyze  the oxidation of steroid 
modulators of γ-aminobutyric acid type A (GABAA) receptors, steroid hormones, 
and xenobiotics  and degradation of isoleucine (Yu Yang et al., 2009). There are 
six mutation reported in HSD17B10 (Korman et al., 2007; Yu Yang et al., 2007; 
Lenski et al., 2007). Yu Yang et al. in 2009 describe the clinical spectrum of 
mutation in HSD17B10 (Yu Yang et al., 2009). The clinical comparisson between 
patients  of Yu Yang et al. and patients in W92-053 are depicted in Table 10.  42 
 
Table 10. Clinical Comparisson between Family W92-053 and previous patients 
with mutation in HSD17B10 
  YUYANG  et  al.  
PATIENT 1  
 
YUYANG 
et  al.  
PATIENT 
2  
MRX10  
 
W92-053  
 
Mutation  
 
c.419C>T   
 
c.776G>C.    
 
c.605C>A 
 
? 
Onset  
 
24 months  
 
6 years  
 
1 years  
 
3 month  
 
Clinical picture  
   MR 
   Regression  
  Gradl  visual 
loss 
  Seizure  
  Early death  
  Other  
 
 
(+) 
(+) 
(+) 
 
(+) 
(+)  
 
 
(+) 
(+) 
 
 
 
 
disarthria  
 
 
(+) 
 
 
 
 
 
Disarthria  
Coreoathetosis  
Abn behaviour  
 
 
(+) 
(+) 
(+) 
 
(+) 
(+)  
 
Ophtalmology  
 
Cortical blindness  
pale optic disk  
 
normal  
 
normal  
 
Pale fundi 
 
Neurology  
 
mild  truncal 
hypotonia  
 
Gait, 
rigidity 
 
Gait,  mild 
spastic 
hypertonia with 
hyperflexia  
 
spastic 
tetraplegia  
 
EEG  
 
Myoclonical 
seizure  
 
Left  focal 
epileptifor
m  
 
 
 
nonspecific 
slow 
dysrhythmia  
 
left 
frontotemporal 
focal   
 
Brain  
 
  CT scan: 
Brain 
atrophy 
Arnold-
Chiari  type 
I  
 
Normal  
 
Autopsy:  brain 
atrophy,  mild 
hypomyelination
,  thyn  gyri, 
delicate  optic 
nerves&corpus 
callosum  
 
Metabolism  
 
3-hydroxy 
2methylbutyril-
CoA 
dehydrogenase 
activity(-)  
 
- 3-
kethotiolase 
deficiency 
- CSF 
lactate ↑  
- ↓complexI  
Normal  
 
Skeletal  age 
retarded 
normal  
 43 
 
The previous patients with mutation in HSD17B10  described by Yu Yang 
et al. had a somewhat more severe clinical course than MRXS10 (table 9). This 
indicates that mutations in HSD17B10 result in a wide clinical spectrum of disease 
in males, ranging from the more severe presentation to the much milder clinical 
course, which may be explained by the difference in mutation type. Our patients 
in  family  W92-053  showed  a  more  severe  clinical  course  than  the  previous 
patients with a mutation in HSD17B10, but have the same features. However, we 
did not find any mutations. Still, HSD17B10 might be the gene, since it is possible 
that these female carrier had complete exon deletion, which would not be seen on 
the sequencing results or that a mutation is located within the intronic region, 
which was not covered by the PCR. This may result in exon skipping, activation 
of  cryptic  splice  sites,  creation  of  a  pseudo-exon  within  an  intron,  or  intron 
retention. RT-PCR will help to show if there is an aberrant transcript. It is also 
possible that the mutation is located in the promoter region of the gene which was 
not covered by the primer we used.  Other possibilities include defects in other 
regulatory  elements,  genetic  or  epigenetic,  involved  in  the  regulation  of 
transcription.  This  might  be  assessed  by  quantitative  real-time  PCR.  
Alternatively, HSD17B10 is not involved in this MR family and other candidate 
genes  have  to  be  considered.  In  fact,  the  region  is  quite  large  (20  Mb)  and 
contains 215 genes including several known XLMR genes.  Development of array 
technology will be able to help to reveal any pathogenic copy number variation on 
genes inside interval. Intervals resulted from linkage analysis also could become 
target of high troughput sequencing which will reveal any gene mutation in these 
intervals. 
In conclussion, we report on a family with mental retardation, spasticity, 
blindness, hypomyelination, early death with a 20 Mb linkage interval in Xp11.3-
q12. One obligate carrier showed extremely skewing XCI. No mutation was found 
on  sequencing  genomic  DNA  of  HSD17B10,  SYP,  SYN1,  UBQLN2  and 
ARGHEF9.   
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Family P03-0452 and 13753/HC (XLMR with Hydrocephalus families) 
Clinical Examination 
 Dutch  families  P03-0452  and  13753/HC  were  referred  to  Moleculer 
Genetic Division RUNMC with congenital hydrocephalus and mental retardation. 
Patient 5037 and 28558 of family P03-0452 also presented with short stature, 
obesity  and  hypogonadism.  Pedigree  of  family  P03-0452  and  W05-111  are 
described in Figure 8 and 9 respectively, both showing X-linked inheritance. 
  
Figure 8.  Pedigree and haplotypes within family P03-0452. The cosegregating 
haplotype has been marked by a black bar. Filled symbols represent male patients 
with MR. 
 
Linkage Analysis 
We performed linkage analysis with 16 markers on the X chromosome. In 
family P03-0452, a maximum two-point LOD score 0.2 was obtained for marker 
DXS1220 (Table 11). It was possible to exclude part of Xp22.2-Xq22.2 (flanked 
by DXS8022 to DXS8096; Table 11) of the X chromosome from linkage (LOD 
score <-2). The interval in region Xq22.2-Xq28 is flanked by marker DXS8096 
and DXS1073. This 51 Mb interval contains 249 annotated genes (NCBI Map 
Viewer build 36.3).   
 
Table 11. Two-Point LOD Scores for 16 X-Chromosomal Markers of family P03-
0452 
Marker 
 
Position 
(cM) 
θ = 0.0 
 
θ =0.05 
 
θ =0.1 
 
θ =0.15 
 
θ =0.2 
 
DXS8022  22.18  -4.69  -0.73  -0.46  -0.32  -0.22 
DXS7110  29.22  0.00  0.00  0.00  0.00  0.00 
DXS1036  33.54  -4.69  -0.73  -0.46  -0.32  -0.22 
DXS8012  42.21  -4.69  -0.73  -0.46  -0.3  -0.22 
DXS1003  47.08  -4.39  -0.72  -0.44  -0.29  -0.19 
DXS1199  52.50  0.00  0.00  0.00  0.00  0.00 
DXS990  60.62  -4.39  -0.72  -0.44  -0.29  -0.19 
DXS8096  68.74  -4.39  -0.72  -0.44  -0.29  -0.19 
DXS1220  70.91  0.17  0.14  0.12  0.10  0.08 45 
 
DXS1212  77.15  0.00  0.00  0.00  0.00  0.00 
DXS1047  82.84  0.00  0.00  0.00  0.00  0.00 
DXS1227  88.33  -4.69  -0.73  -0.46  -0.32  -0.22 
DXS8043  94.22  0.00  0.00  0.00  0.00  0.00 
DXS1193  97.89  0.00  0.00  0.00  0.00  0.00 
DXS1073  102.35  0.00  0.00  0.00  0.00  0.00 
In family 13753/HC, a maximum two-point LOD score 0.6 was obtained 
for marker DXS8012 (Table 12). It was possible to exclude Xp22.33-Xp22.2 of 
the X chromosome from linkage (LOD score <-2). The interval is flanked by 
marker DXS1036 and DXS1073. The 122 Mb interval located in Xp21.1-Xq28 
(UCSC Genome Browser). This is a very large interval covering almost the whole 
X-chromosome.   46 
 
 
Figure 9. Pedigree and haplotype within family 13753/HC. The cosegregating 
haplotype has been marked by a black bar. Filled symbols represent male patients 
with MR. 
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 Table 12. Two-Point LOD Scores for  16 X-Chromosomal Markers of  family 
13753/HC 
Marker 
 
Position 
(cM) 
θ = 0.0 
 
θ =0.05 
 
θ =0.1 
 
θ =0.15 
 
θ =0.2 
 
DXS8022  22.18  -4.39   -1.72  -1.14  -0.81  -0.59 
DXS1036  33.54  0.00  -0.05  -0.10  -0.12  -0.13 
DXS8012  42.21  0.60  0.53  0.47  0.40  0.33 
DXS990  60.62  0.30  0.25  0.21  0.17  0.13 
DXS8096  68.74  0.30  0.25  0.21  0.17  0.13 
DXS1212  77.15  0.00  0.00  0.00  0.00  0.00 
DXS1047  82.84  0.00  0.00  0.00  0.00  0.00 
DXS1227  88.33  0.00  -0.05  -0.10  -0.12  -0.13 
DXS8043  94.22  0.00  0.00  0.00  0.00  0.00 
DXS1193  97.89  0.00  0.00  0.00  0.00  0.00 
DXS1073  102.35  0.00  0.00  0.00  0.00  0.00 
 
X-Chromosome Inactivation Analysis 
X-Chromosome inactivation analysis using analysis of the CGG repeat in 
the  promoter  region  of  FMR1  in  female  29301  on  family  P03-0452  was 
uninformative for FMR1. XCI analysis using analysis of the CAG repeat in the 
promoter  region  of  AR  showed  extremely  skewing  XCI  in  this  female.  XCI 
analysis of female 26744 and 27003 in family 13753/HC showed no skewing XCI 
with FMR1 method which might indicate different genetic defect in this family. 
Overlapping Interval 
Previous  molecular  genetic  studies  showed  X-linked  human  congenital 
hydrocephalus can be caused by  mutations in L1CAM (L1 protein) at Xq28 [Jouet 
et al., 1993] and in AP1S2 at Xp22 (Saillour et al., 2007). However, both family 
P03-0452 and family 13753/HC have been sequenced for L1CAM, which revealed 
no mutation. Linkage analysis now also excludes AP1S2.  Strain et al. in 1994 
reported an interesting X-linked aqueductal stenosis case, in which linkage was 
established outside Xq28, flanked by DXS548 and FRAXA loci in Xq27.3 (Strain 
et  al.,  1994).  This  overlaps  with  the  intervals  in  family  P02-0453  and  family 48 
 
13753/HC.The  overlapping  region  is  7  Mb  and  contains  36  annotated  genes 
(NCBI Map Viewer build 36.3; Figure 10).   
 
 
Figure 10. Candidate genes in the overlapping interval between family P03-0452, 
13753/HC, and previous reported family by Strain et al. 
 
Candidate Gene Selection 
We performed candidate gene prioritization using manual selection and 
bioinformatic tool (ToppGene, available at http://toppgene.cchmc.org).  We used 
known genes for hydrocephalus in human, L1CAM, AP1S2 and NPH, and the 
human orthologous genes of hydrocephalus mouse genes HYDIN, a-SNAP, RFX4, 
FREAC-3, DNAHS, OTX2, MSX1, SOCS7, and MYH10, as training gene and 36 
genes in overlapping interval as test gene. Result of candidate gene prioritization 
with ToppGene are described in Figure 11. FMR1 was shown as a top candidate 
gene. However, mutations in this gene were associated with Fragile-X syndrome, 49 
 
and no previous reports associated with hydrocephalus. Thus we did not choose 
FMR1 as our candidate gene.  
SLITRK2  and  SLITRK4  are  belong  to  SLITRK  family,  which  was 
identified as neuronal transmembrane proteins that play role in regulating neurite 
outgrowth  (Aruga  and  Mikoshiba,  2003).  SLITRK2  and  SLITRK  4  were  all 
predominantly  expressed  in  the  brain  (Aruga,  Yokota,  and  Mikoshiba,  2003).  
Slitrk2  is  strongly  expressed  in  the  ventricular  layer  and  in  neuroepithelium 
adjacent to the third ventricle. Slitrk4 is most strongly expressed in subventricular 
zone and the lateral part of the periaqueductal gray matter (Aruga and Mikoshiba, 
2003). Neurite outgrowth in the ventricle and aquaductus could cause stenosis that 
led into hydrocephalus. Thus, both SLITRK2 and SLITRK4 are good candidate 
genes for hydrocephalus. SLITRK2 and SLITRK4 were selected as candidate genes 
and  sequenced.  No  mutation  was  found  in  SLITRK2  and  SLITRK4  on  patient 
28558 and patient 26857 of family P03-0452 and 13753/HC respectively.  
Genetic Counselling 
No candidate gene mutation was found in these families. However, linkage 
analysis revealed that patient 29301, 5037 and 28558 in family P03-0452 shared 
similar risk haplotype. This finding support X-linked inheritance in this family. 
Thus, each male child of patient 29301 has 50% risk to develop the disorder and 
also, each female child of 29301 has 50% risk to be a carrier.   Linkage analysis 
also showed that patient 26744, 27204, 27003, 26857. This finding support X-
linked  inheritance  in  this  family.  Thus,  sister  of  26857  has  50%  risk  to  be  a 
carrier. This finding can be used for genetic counselling purpose. 
Discussion 
Hydrocephalus is described by abnormalities in the flow or resorption of 
cerebrospinal  fluid  (CSF),  resulting  in  ventricular  dilatation.  Hydrocephalus  is 
categorized  as  congenital,  which  is  present  at  birth  and  often  associated  with 
developmental defects; and acquired, which occurs after development of the brain 
and ventricles (Mori, 1995).  Forty percents of hydrocephalus cases are estimated 
to be caused by genetic factors (Haverkamp et al., 1999; table 13).  50 
 
Although there is strong evidence for genetic causes, only two X-linked 
hydrocephalus genes has been identified so far in humans, which are L1CAM and 
AP1S2.  In  this  study,  we  reported  two  family  with  X-linked  congenital 
hydrocephalus and mental retardation. In both family, L1CAM had already been 
excluded  by  sequencing  and  AP1S2  had  already  been  excluded  by  linkage 
interval. Strain et al in 1994 reported an interesting X-linked aqueductal stenosis 
case, in which linkage was established outside region L1CAM and AP1S2, flanked 
by DXS548 and FRAXA loci in Xq27.3 (Strain et al., 1994).  Thus, we checked 
the shared intervals in family P03-0452, W05-111, and family from Strain et al, 
which results in a 7 Mb overlapping intervals containing 36 genesWe used manual 
selection  and  bioinformatic  tool  (ToppGene,  available  at 
http://toppgene.cchmc.org) to do candidate gene prioritization. ToppGene has an 
advantageous  feature  of  using  mouse  phenotype  from  Mammalian  Phenotype 
(MP) Ontology (Chen et al., 2007), so in this case we could also include human 
orthologous  genes  of  a  mouse  genes  that  were  known  associated  with 
hydrocephalus in mouse model as training genes. SLITRK2, SLITRK4 and CDR1 
were selected as candidate genes.  
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Figure 11. Top 20 candidate genes according to candidate gene prioritization with 
ToppGene for hydrocephalus families. 
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Table 13.  Summary of known loci of hydrocephalus in vertebrates (adopted from 
Zhang et al.,2006) 
 
 
Direct DNA sequencing of SLITRK2 and SLITRK4 on patient 28558 and 
patient  26857  of  family  P03-0452  and  13753/HC  respectively  revealed  no 
mutation.  Still,  we can not  exclude the presence  of deep intronic  or promoter 
mutations  in  SLITRK2  and  SLITRK4.  Moreover,  we  did  not  investigate  the 
presence  of  intragenic  rearrangements  by  techniques  such  as  multiplex  qPCR, 
MLPA or target microarray. Other possibilities, SLITRK2 and SLITRK4 is not 
involved in this MR family.  Development of array technology will be able to help 
to reveal any pathogenic copy number variation on genes inside interval. Intervals 
resulted  from  linkage  analysis  also  could  become  target  of  high  troughput 53 
 
sequencing which will reveal any gene mutation in these intervals. This findings 
suggest the etiological heterogeneity in x-linked hydrocephalus. 
 
Family W07-604 
History 
This  Norwegian  family  was  referred  to  Moleculer  Genetic  Division 
RUNMC with mental retardation and behavioural problems. The pedigree of this 
family is shown in figure 2 Conventional cytogenetic and Fragile-X exclusion had 
already  been  performed  in  Norway  and  showed  no  abnormalities.  Linkage 
analysis that had been performed in Norway indicated linkage to Xp21.1-Xp22.2. 
 
 
Figure 12. Pedigree of family W07-604. 
 
X-Chromosome Inactivation Analysis 
Skewing of X inactivation was investigated via analysis of the CGG repeat 
in the promoter region of FMR1. The tested carrier females (IV.1) showing no 
skewing XCI with FMR1 method. 
250K SNP Array Analysis 
Affymetrix  250K    SNP  Array  analysis  (Figure  13)  of  patients  III.9 
identified    4.6  Mb  deletion  of  the  pter  of  chromosome  9  (last  deleted  SNP: 
SNP_A-2236672) and 5 Mb duplication of pter chromosome 2 (pTer; SNP_A-
1786649 and a small piece right next to this duplicated region: SNP_A-1917548; 54 
 
SNP_A-4199698;  first  or  last  duplicated  SNPs  given),  which  suggested  a 
unbalanced translocation t(2;9)(p25.2;p24.2) 
Discussion 
We reported a family with mental retardation and behavioural problems. 
Conventional cytogenetic  analysis  did  not  show  any  abnormalities.This  family 
was assumed to be X-linked due to the type of inheritance showed by pedigree. 
Linkage analysis had been performed in this family, showing linkage interval on 
Xp21.1-Xp22.2.  However,  we  identified  a  deletion  of  chromosome  9p  and 
duplication  of  chromosome  2p,  suggesting  an  unbalanced  translocation 
t(2;9)(p25.2;p24.2). 
There  have  been  a number of studies about 9p deletion syndrome that 
reported several clinical features for this syndrome including mental retardation, 
trigonocephaly, low set ears and dysmorphic facial features, such as up-slanting 
palpebral fissures and a long philtrum (Huret et al., 1988; Swinkels et al., 2008; 
Hauge et al., 2008). Our patients only showed mental retardation and behavioural 
problems, which also were reported in the previous 9p deletion syndrome cases 
(table 14).  
About the consequences of a duplication of chromosome 2p less is known. 
There  were  rare  reports  about  partial  trisomy  2p,  which  indicate  serious 
complications  including:  diaphragmatic  hernia  (2p23-p25),  neural  tube  defects 
(2p24), broncho-pulmonary anomalies (2p21-p25), and congenital heart defects 
(2p23-p24). However, in most cases the duplication involves larger regions from 
2pter up to band 2p21 (Lurie et al., 1995). 
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Figure 13. 250K SNP array data on the family W07-604 patient III.9 showing a 
(A) 4.6 Mb deletion of chromosome 9 involving region 9p24.3-p24.2 and (B) 5 
Mb duplication within 2p25.3-2p25.2 (Figure 13.B).   
 
To  our  knowledge,  there  was  only  one  pure  duplication  case  with  a 
duplication as distal as in the patient reported here (Wakita et al., 1985).  In that 
case, patient showed trigonocephaly, hypertelorism, mongoloid slant of palpebral 
fissures,  right  exophthalmos,  anteverted  nostrils,  low-set  and  malformed  ears, 
arachnodactyly, and contractures of the elbow joints and interphalangeal joints of 
fingers  II-V,  and  normal  psychomotor  development.    None  of  those  clinical 
features were found in our patient. Altogether, the duplication of the terminal part 56 
 
of chromosome 2p may only mildly contribute to the phenotype of the patient 
described here. 
 
Tabel 14.  Comparisson of clinical features of patient IV.9 from family W07-604 
with previous reported cases of 9p deletion syndromes. 
Clinical 
Features  
Huret et 
al  
Swinkels 
et al  
Hauge et al  Our 
patient  
12   13   1   2   3   4   5  
MR   36/36   +   +   +   +   +   +   +   +  
Behaviour   U       +   +   +   +   +   +  
Head   Trigonoc
ephaly 
32/32  
-   -   -   -   pro
min
ent  
trigon
oceph
aly  
-   -  
Ears   low set 
ears 
27/30  
-   -   -   +   +   +   -   - 
Long philtrum   32/32   +   -   -   +   +   U   +   - 
Midface 
hypoplasia  
6/7   +   -   -   -   +   U   +   - 
Arching 
eyebrows  
9/12   -   -   -   +   Med
ial 
flare  
U   -   - 
Broad 
internipple  
31/31   U   U   -   -   U   +   U   - 
Hand/foot                   - 
Genitourinary   15/36   +   +   -   U   U   APA   -   - 
Cardiovascular  16/35  -  -  U  -  U  R Ao 
Arch 
-  - 
 
Family anamnesis suggested that the genetic defect in family W07-604 
was linked to the X chromosome. However, additional STR markers analysis in 
healthy  male  III.4  conducted  after  finishing  this  study  excluded  the  original 
linkage interval. By affymetrix 250K  SNP Array analysis of patients III.9, we 57 
 
now  identified  a  4.6  Mb  deletion  of  the  pter  of  chromosome  9  and  5  Mb 
duplication  of  pter  chromosome  2  which  suggests  there  is  an  unbalanced 
translocation t(2;9)(p25.2;p24.2). Further examinations are needed to confirmed 
the deletion and duplication in patients, also to check whether this aberration de 
novo or also segregated in parents. FISH analysis will be able to show balanced 
translocation in patients and unbalanced translocation in carrier parents. Another 
affected  member  of family  also  need  to  be  checked  to  see  whether  they  also 
shared similar unbalanced translocation. FISH, MLPA and qPCR could help to 
check the translocation in other affected family members. It is still possible that  
the  MR  in  other  family  members  cannot  be  explained  by  the  unbalanced 
translocation in patient IV.9. 
  
 
  Family DF27004 (MR and Overgrowth Features) 
Clinical Examination 
Dutch  families  DF27004  (Fig.  14)  were  referred  to  Moleculer  Genetic 
Division RUNMC with mental retardation and overgrowth syndrome. Pedigree of 
this four generation family showed X-linked inheritance. The propositus, 33431, 
showed  mental  retardation,  macrocephaly,  hepatomegaly,  kidney  enlargement. 
Other affected boy, 91105 showed  similar features.  Obligate carriers were said to 
be normal. 
Genetic Analysis 
Gross  cytogenetic  abnormalities  and fragile-X  already  excluded  before.  
Following  the  hypothesis  of  an  X-linked  disorder,  linkage  analysis  was  then 
performed  with  sixteen  highly  polymorphic  markers  spanning  the  entire  X-
chromosome  were  used  for  linkage  analysis  (Table  15).  This  family  showed 
intervals of 37 Mb and 9.5 Mb in Xp22.2-Xq11.2 and Xq27.3-Xq28 respectively 
(maximum LOD score of 1.62 at θ=0,0 for DXS8022) that segregated with the 
disease.  X-chromosome inactivation analysis in  obligate carrier 4984, showed  
no skewing XCI.   58 
 
The  overgrowth  features  (macrocephaly,  hepatomegaly,  and  renal 
enlargement) in this cases lead suspicion to Simpson-Golabi-Behmel syndrome 
(SGBS)  -primarily  characterized  by  overgrowth-    as  a  differential  diagnosis. 
SGBS is caused by mutation in GPC3 gene and OFD1 gene.  However, sequence 
analysis of GPC3 coding region in patient 33431 did not revealed any pathogenic 
point mutation.   
 
Table  15.  Two-Point  LOD  Scores  for  16  X-Chromosomal  Markers  of  family 
DF27004 
Marker 
 
Position 
(cM) 
θ = 0.0 
 
θ =0.05 
 
θ =0.1 
 
θ =0.15 
 
θ =0.2 
 
DXS7108  18.37  -0.65  -0.36  -0.21  -0.12  -0.06 
DXS7104  20.27  -0.02  -0.02  -0.02  -0.02  -0.01 
DXS8022  22.18  1.62  1.45  1.28  1.11  0.92 
DXS7110  29.22  1.32  1.19  1.05  0.91  0.76 
DXS1036  33.54  -0.67  -0.62  -0.51  -0.40  -0.30 
DXS8090  36.79  -0.67  -0.49  -0.28  -0.12  -0.02 
DXS8012  42.21  0.44  0.41  0.36  0.32  0.28 
DXS1003  47.08  0.00  0.00  0.00  0.00  0.00 
DXS1199  52.50  0.00  0.00  0.00  0.00  0.00 
DXS990  60.62  -2.37  -1.27  -0.86  -0.59  -0.39 
DXS8020  65.50  0.04  0.02  0.00  -0.01  -0.01 
DXS8096  68.74  -0.67  -0.52  -0.32  -0.18  -0.07 
DXS1059  68.75  -0.55  -0.39  -0.28  -0.20  -0.14 
DXS1220  70.91  -0.67  -0.58  -0.44  -0.32  -0.22 
DXS1212  77.15  -0.63  -0.40  -0.27  -0.17  -0.11 
DXS1047  82.84  0.18  0.17  0.16  0.14  0.13 
DXS8094  82.85  -0.37  -0.32  -0.22  -0.14  -0.07 
DXS1192  83.92  -0.37  -0.38  -0.36  -0.29  -0.22 
DXS984  85.55  -0.22  -0.17  -0.13  -0.09  -0.06 
DXS1227  88.33  0.00  0.00  0.00  0.00  0.00 
DXS8028  95.13  0.46  0.42  0.37  0.31  0.26 
DXS8091  97.89  1.03  0.89  0.75  0.62  0.49 
DXS1193  97.89  0.21  0.20  0.19  0.17  0.15 
DXS1073  102.35  -0.37  -0.37  -0.33  -0.28  -0.22 
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Discussion 
We report a three generation family in which an X-linked trait seems to 
segregate. This family present with overgrowth features and mental retardation. 
There are  several overgrowth  syndromes which  show overlapping clinical  and 
molecular  features,  such  as:  Beckwith-Wiedemann,  Pallister-Killian,  Soto, 
Perlman,  and  Simpson-Golabi-Behmel  syndrome  (Vora  and  Bianchi,  2009). 
Among  those  syndromes,  only    Simpson-Golabi-Behmel  syndrome    (SGBS) 
shows  X-linked  inheritance.  Patients  with  SGBS  have  pre-  and  postnatal 
overgrowth, coarse facies, congenitalheart defects, cleft lip and palate, enlarged 
and dysplastic kidneys, skeletal abnormalities, and an increased risk of embryonal 
tumours (Hughes et al., 1992).  This syndrome can be caused by mutations in 
GPC3 or OFD1.  GPC3 is a membrane associated heparan sulphate proteoglycan, 
which  is    a  member  of  the  glypican  related  integral  membrane  proteoglycans 
(GRIPS). This gene are known to modulate the interaction between growth factors 
and receptors (Pilia et  al., 1996). Functional data confirm GPC3 as an excellent 
candidate gene, as Gpc3-deficient mice show developmental overgrowth (Cano-
Gauci et al., 1999). We thus performed GPC3 mutational screening in patient 
33431, but we could not find any mutations. Still, GPC3 might be the gene, since 
it is possible that a mutation is located within the intronic region, which was not 
covered by the PCR. This may result in exon skipping, activation of cryptic splice 
sites, creation of a pseudo-exon within an intron, or intron retention. RT-PCR will 
help to show if there is an aberrant transcript. It is also possible that the mutation 
is located in the promoter region of the gene which was not covered by the primer 
we used.  Other possibilities include defects in other regulatory elements, genetic 
or epigenetic, involved in the regulation of transcription. This might be assessed 
by quantitative real-time PCR.  Alternatively, GPC3 is not involved in this MR 
family and other candidate genes have to be considered. In fact, the region is quite 
large (37.5 Mb and 9 Mb) and contains hundreds genes including several known 
XLMR genes.  Development of array technology will be able to help to reveal any 
pathogenic copy number variation on genes inside interval. Intervals resulted from 60 
 
linkage analysis also could become target of high troughput sequencing which 
will reveal any gene mutation in these intervals. 
In summary, we reported a family with mental retardation and overgrowth 
features with intervals of 37 Mb and 9.5 Mb in Xp22.2-Xq11.2 and Xq27.3-Xq28 
respectively.  One  obligate  carrier  showed  no  skewing  XCI.  No  mutation  was 
found on sequencing genomic DNA of GPC3.   61 
 
 
 
 
 
 
 
Figure  14.   Family DF27004:  Pedigree  and  haplotypes. The cosegregating haplotypes  has been marking  by  black bar.  Filled 
symbols represents male patients with MR.   
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Family W09-0071, W09-0072, W09-0074, W009-0079, and W08-2152 
W09-0071 Clinical Reports 
 
Figure  15.  Family  W090-0071:  Pedigree  and  haplotype.  The  cosegregating 
haplotypes  has  been  marking  by  black  bar.  Filled  symbols  represents  male 
patients with MR.   63 
 
Family W09-0071 (Fig.15) was ascertained by purposive sampling in a 
special  school.  The  pedigree  of  this  family  was  compatible  with  X-linked 
inheritance. Not much is known about the past medical history of the patients. 
Patient 50156 was attending a special school, while patient 50160 was kept at 
home by his parents. Obligate carriers were said to be normal. 
The propositus, 50156, was examined at age 8 years. He had high arched 
palate, tappering pad, sandal gap, soft fleshy hands and short third toe (Fig .16). 
His behaviour was unremarkable. Patient 50160 was seen at the age of 11 years. 
Soft  fleshy  hands,  sandal  gap,  pes  planus  and  macroorchidism  were  noted 
(Fig.16). His behaviour was difficult to control. 
     
A          B                       C 
     
D                  E 
Figure  16.  Clinical  pictures  of  family  W09-00071.  (A)  facial  appearance  of 
Patient 50156. This patient showed  (B) shoft fleshy hands and (C) short third toe. 
(D) facial appearance of patient 50160. This patient showed (E) shoft fleshy hand. 64 
 
The overall intellectual capacities of the tested patients (50156 and 50160) 
were rated as below average with the onset of before age of 18. Therefore both 
patient 50156 and 50160 were classified as mentally retarded.  
Microscopic cytogenetic analysis in patient 50156 and 50160 showed no 
chromosomal abnormalities. Analysis of CGG repeat on the promoter region of 
FMR1 on patient 50156 showed no CGG repeat expansion. Twenty-three highly 
polymorphic  markers  were  used  for  linkage  analysis  (Table  16).  This  family 
showed two intervals of 8 Mb and 81 Mb in region Xp22.2-Xp22.11 and Xp11.4-
Xq25 (maximum LOD score of 0.75 at θ=0,0 for DXS1047) that segregated with 
the disease.  It was possible to exclude Xp22.33-Xp22.22 and Xp21.1-Xp11.4 of 
the X-chromosome from linkage (LOD score <-2), marked by marker DXS8022 
and DXS8090. X-chromosome inactivation analysis in  obligate carrier 50157 and 
50161 showed no skewing XCI.   
 
Table 16. Two-Point LOD Scores for X-Chromosomal Markers of family W09-
071 
Marker 
 
Position 
(cM) 
θ = 0.0 
 
θ =0.05 
 
θ =0.1 
 
θ =0.15 
 
θ =0.2 
 
DXS8022  22.18  -5.80  -1.95  -1.39  -1.01  -0.73 
DXS8036  22.72  0.12  0.11  0.10  0.09  0.07 
DXS8019  23.26  0.52  0.43  0.34  0.25  0.17 
DXS7163  23.26  -1.11  -1.14  -1.11  -0.98  -0.81 
DXS7110  29.22  0.00  0.00  0.00  0.00  0.00 
DXS1036  33.54  0.02  0.02  0.01  0.01  0.01 
DXS8090  36.79  -5.81  -1.95  -1.39  -1.01  -0.73 
DXS8012  42.21  -1.58  -0.58  -0.34  -0.21  -0.14 
DXS1003  47.08  0.06  0.04  0.03  0.02  0.01 
DXS1204  52.50  0.41  0.36  0.31  0.25  0.20 
DXS1275  55.75  0.73  0.64  0.55  0.46  0.37 
DXS1221  57.37  0.00  0.00  0.00  0.00  0.00 
DXS990  60.62  0.72  0.63  0.53  0.44  0.35 
DXS8077  62.52  0.07  0.05  0.04  0.03  0.02 
DXS8020  65.50  0.04  0.03  0.02  0.02  0.01 
DXS8096  68.74  -1.10  -1.14  -1.10  -0.98  -0.81 
DXS1059  68.75  0.74  0.66  0.57  0.48  0.39 
DXS1047  82.84  0.75  0.66  0.57  0.48  0.39 65 
 
Marker 
 
Position 
(cM) 
θ = 0.0 
 
θ =0.05 
 
θ =0.1 
 
θ =0.15 
 
θ =0.2 
 
DXS1227  88.33  0.04  0.03  0.02  0.02  0.01 
DXS8043  94.22  0.72  0.63  0.54  0.46  0.37 
DXS1200  96.94  0.12  0.10  0.08  0.07  0.05 
DXS1193  97.89  0.05  0.04  0.03  0.02  0.02 
DXS1073  102.35  0.47  0.40  0.32  0.26  0.19 
 
Genetic Counselling 
Although the linkage interval found in this family is quite big, still it can 
be used to show risk haplotype in this family. It was found that patient 50157, 
50161, 50159, 50156 and 50160 shared risk haplotype. This finding support X-
linked  inheritance in this family.  The mother  shared risk  haplotype with their 
affected son. Interestingly, healthy female 50159 shared similar risk haplotype 
with the other affected male, but in narrower scale. Thus, there is a chance that 
she  is  a  carrier,  except  if  the  genetic  defect  lie  in  between  DXS1204  and 
DXS8020. This finding was used for genetic counselling purposes.   
Parents  in  this  family  come  from  high  education  and  high  income 
background.  The  first  information  whas  shared  with  carrier  mother  50157, 
considering that the daughter 50159 shared risk haplotype. Additional information 
from carrier mother 50157 revealed more affected male family members from 
maternal  side.  This  information  supports  X-linked  inheritance  in  this  family. 
Despite of her high educational background,  carrier mother 50157 refused to 
share  the  information  to  other  family  members.  From  previous  experience  in 
Indonesia, it seems that Indonesian parents with higher educational profile  are 
less willing to cooperate in carrier testing. Genetic counselling in such family 
often lead to divorce and aversion from the counsellor (Faradz et al., 2010).  66 
 
 
W09-0072 Clinical Report 
 
 
Figure  17.  Family  W090-0072:  Pedigree  and  haplotypes.  The  cosegregating 
haplotypes  has  been  marking  by  black  bar.  Filled  symbols  represents  male 
patients with MR.   
 
The  family  W09-0072  (Fig.  17)  was  was  ascertained  by  purposive 
sampling in a special school. The pedigree of this family was compatible with X-
linked  inheritance.  Not  much  is  known  about  the  past  medical  history  of  the 
patients. Patient 50164 and 50168 were attending special school, while patient 
50169 was kept at home by his parents. Obligate carriers were said to be normal. 
  The propositus, 50164 (Fig. 18A), was examined at age 13 years. He had 
long face, heavy eyebrows, broad nasal bridge, prominent ears, sandal gaps, and 
pes planus. Patient 50168 (Fig 18B) was examined at age 16 years. He had long 
face, heavy eyebrows, broad nasal bridge, and prominent ears. Patient 50169 (Fig 
18C) was seen at the age of 11 years. No facial dysmorphism was noted in this 
patient. Their behaviour were unremarkable.   
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    A        B      C     
Figure 18. Clinical picture of family W09-072: This patient showed long face, 
heavy eyebrows, broad nasal  bridge, prominent ears  in patient 50164  (A)  and  
patient 50168 (B). No facial dysmorphism in patient 50169 (C).  
 
Microscopic  cytogenetic  analysis  in  patient  50164,  50168  and  50169 
showed no chromosomal abnormalities. Analysis of CGG repeat on the promoter 
region  of  FMR1  on  patient  50164  showed  no  CGG  repeat  expansion.  Fifteen 
highly  polymorphic  markers  were  used  for  linkage  analysis  (Table  17).  This 
family showed an intervals of 32 Mb in region Xp22.2-Xp11.3 (maximum LOD 
score of 0.91 at θ=0,0 for DXS8022) that segregated with the disease.  It was 
possible to exclude Xp11.4-Xq28 of the X-chromosome from linkage (LOD score 
<-2),  marked  by  marker  DXS8012  to  DXS1193.  X-chromosome  inactivation 
analysis showerd skewing XCI in obligate carrier 50165 and no skewing XCI in 
carrier 50170.  
 
Genetic Counselling 
Although the linkage interval found in this family is quite big, still it can 
be used to show risk haplotype in this family. It was found that patient 50165, 
50170,  50164,  50167,  50168,  and  50169  shared  risk  haplotype.  This  finding 
support X-linked inheritance in this family. The mother shared risk haplotype with 
their  affected  son.  Interestingly,  healthy  female  50167  shared  similar  risk 
haplotype with the other affected male and female, but in narrower scale. Thus, 68 
 
there is a chance that she is a carrier, except if the genetic defect lie in between 
DXS8090  and  DXS8020.  This  finding  can  be  used  for  genetic  counselling 
purposes.   
 
Table  17.  Two-Point  LOD  Scores  for  16  X-Chromosomal  Markers  of  family 
W09-072 
Marker 
 
Position 
(cM) 
θ = 0.0 
 
θ =0.05 
 
θ =0.1 
 
θ =0.15 
 
θ =0.2 
 
DXS8022  22.18  0.91  0.81  0.71  0.61  0.50 
DXS7110  29.22  -0.01  -0.01  -0.01  -0.01  -0.01 
DXS1036  33.54  0.00  0.00  0.00  0.00  0.00 
DXS8090  36.79  0.36  0.31  0.26  0.20  0.16 
DXS8012  42.21  -2.86  -0.72  -0.45  -0.31  -0.21 
DXS1003  47.08  -2.86  -0.72   -0.45   -0.31   -0.21  
DXS1199  52.50  -8.97    -1.5   -0.98    -0.66   -0.44 
DXS990  60.62  -4.87  -0.41  -0.18  -0.08  -0.03 
DXS8096  68.74  -4.82  -0.65  -0.39  -0.25  -0.16 
DXS1212  77.15  -8.97  -1.57  -0.98  -0.66  -0.44 
DXS1047  82.84  -0.02  -0.01  -0.01  -0.01  -0.01 
DXS1227  88.33  -4.57  -0.85  -0.54  -0.36  -0.24 
DXS8043  94.22  -1.89  -0.66  -0.40  -0.26  -0.17 
DXS1193  97.89  -2.57  -0.62  -0.38  -0.25  -0.17 
DXS1073  102.35  0.22  0.19  0.15  0.11  0.08 
 
 
W09-0074 Clinical Reports 
The family W09-0074 (Fig. 19) was ascertained by purposive sampling in 
a  special  school.  The  pedigree  of  this  family  was  compatible  with  X-linked 
inheritance. Not much is known about the past medical history of the patients. 
Patient 50176 and 50177 were attending special school. Obligate carriers were 
said to be normal. 
  The propositus, 50176 (Fig 20A), was examined at age 14 years. Patient 
50177 (Fig 20B) was examined at age 12 years. Both patients showed large 
prominent ears and macroorchidism. Their behaviour were unremarkable. 
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Figure  19.  Family  W090-0074:  Pedigree  and  haplotype.  The  cosegregating 
haplotypes  has  been  marking  by  black  bar.  Filled  symbols  represents  male 
patients with MR.   
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Figure  20.  Pasien  50176  (A)  and  patient  50177  (B).  Those  patients  showed 
prominent ears. 
 
Microscopic cytogenetic analysis in patient 50176 and 50177 showed no 
chromosomal abnormalities. Analysis of CGG repeat on the promoter region of 
FMR1 on both patients  showed no CGG repeat expansion. Previous MLPA with 
subtelomeric  probes  showed  no  subtelomeric  rearrangement.  Fifteen  highly 
polymorphic  markers  were  used  for  linkage  analysis  (Table  18).  This  family 
showed two intervals of 32 Mb and 31 Mb in region Xp22.2-xp11.3 and Xq25-
Xq28 (maximum LOD score of 0.3 at θ=0,0) that segregated with the disease.  It 
was possible to exclude Xp22.33-Xp22.22 and Xq22.2-Xq25 from linkage (LOD 
score <-2). X-chromosome inactivation analysis in  obligate carrier 50178 showed 
no skewing XCI.   
Genetic Counselling 
Although the linkage interval found in this family is quite big, still it can 
be used to show risk haplotype in this family. It was found that patient 50157, 
50178, 50177, and 50176 shared risk haplotype. This finding support X-linked 
inheritance in this family. The mother shared risk haplotype with their affected 
son. This finding can be used for genetic counselling purposes.   
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Table  18.  Two-Point  LOD  Scores  for  16  X-Chromosomal  Markers  of  family 
W09-074 
Marker 
 
Position 
(cM) 
θ = 0.0 
 
θ =0.05 
 
θ =0.1 
 
θ =0.15 
 
θ =0.2 
 
DXS8022  22.18   -4.69  -0.72  -0.44  -0.29  -0.19 
DXS7110  29.22  0.30  0.25  0.21  0.17  0.13 
DXS1036  33.54  0.30  0.25  0.21  0.17  0.13 
DXS8090  36.79  0.00  0.00  0.00  0.00  0.00 
DXS8012  42.21  0.00  0.00  0.00  0.00  0.00 
DXS1003  47.08  -4.69  -0.72  -0.44  -0.29  -0.19 
DXS1199  52.50  0.00  0.00  0.00  0.00  0.00 
DXS990  60.62  0.00  0.00  0.00  0.00  0.00 
DXS8096  68.74  -4.69  -0.72  -0.44  -0.29  -0.19 
DXS1212  77.15  -4.69  -0.72  -0.44  -0.29  -0.19 
DXS1047  82.84  0.30  0.25  0.21  0.17  0.13 
DXS1227  88.33  0.00  0.00  0.00  0.00  0.00 
DXS8043  94.22  0.00  0.00  0.00  0.00  0.00 
DXS1193  97.89  0.00  0.00  0.00  0.00  0.00 
DXS1073  102.35  0.30  0.25  0.21  0.17  0.13 
 
W09-0078 Clinical Reports 
The family W09-0078 (Fig. 21) was ascertained by purposive sampling in 
a  special  school.  The  pedigree  of  this  family  was  compatible  with  X-linked 
inheritance. Not much is known about the past medical history of the patients. 
Patient 50215, 50196 and 50122 were attending special school. Obligate carriers 
were said to be normal. 
  The  propositus,  50215  (Fig    22),  was  examined  at  age  12  years.  He 
showed long face, heavy eyebrow, prominent ears, soft fleshy hands, sandal gap, and pes 
planus. His behaviour was unremarkable. 
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Figure 21.  Family W090-0078: Pedigree and haplotypes. The cosegregating haplotypes has been marking by black bar. Filled symbols represents male patients with MR. 73 
 
   
    A          B 
Fig 22. Patient 50196 from Family W09-078:  This patient showed long face, 
heavy eyebrow, prominent ears (A), and soft fleshy hands (B).  
 
Microscopic  cytogenetic  analysis  in  patient  50215,  50196  and  50122 
showed no chromosomal abnormalities. Analysis of CGG repeat on the promoter 
region of FMR1 on patient 50196  showed no CGG repeat expansion. Previous 
MLPA with subtelomeric probes showed no subtelomeric rearrangement. Sixteen 
highly  polymorphic  markers  were  used  for  linkage  analysis  (Table  19).  This 
family showed two intervals of 32 Mb and 31 Mb in region Xp22.2-xp11.3 and 
Xq25-Xq28 (maximum LOD score of 1.39 at θ=0,0 for DXS1212) that segregated 
with the diseaseX-chromosome inactivation analysis in  obligate carrier 50207, 
50198, and 50209 showed no skewing XCI.   
 
Table 19. Two-Point LOD Scores for X-Chromosomal Markers of family W09-
078 
Marker 
 
Position 
(cM) 
θ = 0.0 
 
θ =0.05 
 
θ =0.1 
 
θ =0.15 
 
θ =0.2 
 
DXS8022  22.18  -2.22  -2.03  -1.27  -0.84  -0.56 
DXS7110  29.22  -4.81  -1.31  -0.82  -0.55  -0.36 
DXS1036  33.54  0.58  0.52  0.45  0.38  0.30 
DXS8090  36.79  0.00  0.00  0.00  0.00  0.00 
DXS8012  42.21  -2.51  -1.46  -1.01  -0.74  -0.54 
DXS1003  47.08  -1.62  0.07  0.25  0.31  0.31 
DXS1199  52.50  0.00  0.00  0.00  0.00  0.00 
Marker  Position  θ = 0.0  θ =0.05  θ =0.1  θ =0.15  θ =0.2 74 
 
  (cM)           
DXS990  60.62  -1.65  -1.19  -0.68  -0.42  -0.26 
DXS8096  68.74  0.00  0.00  0.00  0.00  0.00 
DXS1220  70.91  -2.21  -1.4  -1.20  -0.98  -0.78 
DXS1212  77.15  1.39  1.23  1.07  0.90  0.73 
DXS1047  82.84  0.00  0.00  0.00  0.00  0.00 
DXS1227  88.33  -1.41  -0.65  -0.41  -0.27  -0.18 
DXS8043  94.22  -1.22  -0.84  -0.40  -0.18  -0.06 
DXS1193  97.89  -1.11  -0.38  -0.17  -0.05  0.01 
DXS1073  102.35  -0.81  -0.12  0.04  0.10  0.12 
 
Genetic Counselling 
Although the linkage interval found in this family is quite big, still it can 
be used to show risk haplotype in this family. It was found that obligate carrier 
50207, 50198 and 50209 shared similar risk haplotype with their affected son. 
This finding support X-linked inheritance in this family. The mother shared risk 
haplotype  with  their  affected  son.  Interestingly,  females  50202,50203,  50204, 
50205, shared similar risk haplotype with obligate carrier and affected male. Thus 
they can be a carrier, except if the genetic defect lie in between DXS1212 and 
DXS8043 which is uninformative in this family. This finding can be used for 
genetic counselling purposes.   
 
W08-2152 Clinical Reports 
Dutch families W08-2152 (Fig. 23) were referred to Moleculer Genetic 
Division RUNMC with mental retardation and behavioural problem. The pedigree 
of  this family  was  compatible  with  X-linked  inheritance.  Not  much  is known 
about the past medical history of the patients.  Obligate carriers were said to be 
normal. The propositus, 49744, showed mental retardation, autism, epilepsy, long 
narrow    face,  deep  set  eyes,  high  nasal  bridge,  macroorchidism,  short  fifth 
metatarsal, long finger and toes. Other affected boys, 49745 and 49746, showed  
similar features.   
Gross  cytogenetic  abnormalities  and fragile-X  already  excluded  before.  
Sixteen highly polymorphic markers were used for linkage analysis (Table 20). 
This family showed one interval of 31 Mb in region Xq25-Xq28 (maximum LOD 75 
 
score of 1.36 at θ=0,0 for DXS1193) that segregated with the disease.  It was 
possible to exclude Xp22.2-Xq22.2 (flanked by DXS1060 and DXS1106) from 
linkage (LOD score <-2). X-chromosome inactivation analysis in  obligate carrier 
51677, showed skewing XCI.   
 
Table 20. Two-Point LOD Scores for X-Chromosomal Markers of family W08-
2152 
Marker 
 
Position 
(cM) 
θ = 0.0 
 
θ =0.05 
 
θ =0.1 
 
θ =0.15 
 
θ =0.2 
 
DXS1060  15.12  -11.62  -1.65  -1.31  -1.03  -0.78 
DXS8051  17.29  -6.84  -0.57  -0.38  -0.29  -0.25 
DXS8022  22.18  -14.72  -1.11  -0.87  -0.71  -0.57 
DXS987  22.18  -9.62  -1.65  -1.32  -1.04  -0.79 
DXS1226  27.59  -9.62  -1.46  -0.94  -0.62  -0.41 
DXS7110   29.22  -9.32  -1.37  -0.82  -0.50  -0.30 
DXS1214  33.54  -6.84  -0.57  -0.37  -0.29  -0.25 
DXS1036  33.54  -9.32  -1.37  -0.82  -0.50  -0.30 
DXS8090   36.79  -9.32  -1.37  -0.82  -0.50  -0.30 
DXS1068  37.33  0.00  0.00  0.00  0.00  0.00 
DXS993  42.21  -9.62  -1.45  -0.94  -0.62  -0.41 
DXS8012  42.21  -9.32  -1.37  -0.82  -0.50  -0.30 
DXS1003  47.08  -9.02  -1.11  -0.88  -0.74  -0.62 
DXS1199   52.50  -0.76  -0.70  -0.56  -0.42  -0.30 
DXS991    52.50  -11.62  -1.65  -1.31  -1.03  -0.78 
DXS986  57.38  -11.62  -1.65  -1.31  -1.03  -0.78 
DXS990  60.62  -0.62  -0.55  -0.42  -0.31  -0.22 
DXS1106  68.74  -9.92  -0.85  -0.43  -0.23  -0.13 
DXS1220  70.91  0.00  0.00  0.00  0.00  0.00 
DXS1001  75.79  1.16  1.05  0.94  0.81  0.68 
DXS1047  82.84  -0.32  -0.38  -0.45  -0.49  -0.49 
DXS1227  88.33  0.00  0.00  0.00  0.00  0.00 
DXS8043  94.22  0.00  0.00  0.00  0.00  0.00 
DXS8091  97.89  -0.62  -0.65  -0.63  -0.55  -0.45 
DXS1193  97.89  1.36  1.23  1.09  0.95  0.80 
DXS1073  102.35  -0.62  0.03  0.18  0.23  0.23 
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Figure 23.  Family W08-2152: Pedigree and haplotypes. The cosegregating haplotypes has been marking by black bar. Filled symbols represents 
male patients with MR.  77 
 
Discussion 
We presented 5 families with non specific  XLMR. All affected males in 
each of the families did not show any consistent clinical findings apart from MR, 
which lead to nonspesific XLMR as an appropriate diagnosis. Obligate carriers in 
all  families  showed  normal  intelligence.  Based  on  three  criteria  of  mental 
retardation  all  affected  male  from  the  5  families  were  classified  as  mentally 
retarded. The degree of mental retardation showed variation within each family, 
ranging from mild to profound. 
We have found interval to specific regions of the X-chromosome in all 
those 5 families with X-linked mental retardation. However, LOD score  from 
those families are below 2, and interval found were large containing high number 
of  genes.  Addition  of  other  family  members,  especially  the  affected  family 
members, will help to narrow down the interval. Linkage result from this families 
can be used for genetic counselling purpose, considering that linkage will show 
risk haplotype in probable carrier. 
Due  to  non  specific  clinical  phenotype  and  large  interval  found,  it  is 
difficult to choose the candidate gene in the intervals region.  Development of 
array technology will help to reveal any pathogenic copy number variation on 
genes inside interval. Intervals resulted from linkage analysis also could become 
target of high troughput sequencing which will help to reveal any gene mutation 
in these intervals. 
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CHAPTER V 
CONCLUSION AND SUGGESTION 
 
V.1. Conclusion 
1.  Identification of genetic defect in four syndromic and six non-syndromic 
XLMR families showed no macroscopic chromosomal abnormalities nor a 
CGG expansion in 5’ untranslated region of FMR1. Ten XLMR families 
studied showed linkage intervals varying in size from 20 Mb to 121 Mb 
with varying LOD scores from 0.7 to 3.3.  
2.  Four families showed skewed X-inactivation in the obligate carrier female. 
3.  Candidate  genes  were  selected  in  four  syndromic  XLMR  families.  No 
mutation was found in the those candidate genes. Candidate selection is 
easier to perform in the syndromic- compared to non-syndromic XLMR 
families, although no causative gene was found yet.  
 
V.2. Suggestion 
In all 10 families STR markers analysis was useful to determine linkage 
intervals. Although these are still large linkage intervals, we could narrow down 
the region of interest for further studies, such as next generation sequencing of the 
X-chromosome. In future studies, a more detailed clinical work-up need to be 
considered in order to  find specific clinical features that could help in selection of 
candidate  genes.  Addition  of  DNA  from  other  family  members  will  help  to 
establish  smaller  linkage  intervals  and  to  increase  LOD  scores.  In  addition, 
linkage interval found in this study can be useful for genetic counselling purpose, 
especially to diagnose carrier.This study also presents a workflow that will be 
very useful to implement in future studies of XLMR cases in Indonesia (Appendix 
VII). In addition, workflow used in two cases of X-linked hydrocephalus and  MR 
in this study can be used for future studies of X-linked hydrocephalus and MR in 
Indonesia (Appendix VIII).  
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APPENDIX I:   
Chromosomal Preparation  
 
Methods: 
Ten  drops  of heparinized blood were  cultured into two different 5 mL 
media (TC99 and MEM), to each 5% Fetal Bovine Serum (FBS) and 0,025 
mL Phytohemaglutinin-P (Gibco) was added and incubated at 37°C for 72 
hours. 0.1 mL thymidine (final concentration of 0.3 µg/m) was added to 
MEM media tube 24 hour before further processing, followed by addition 
of  3  drops  of  colchicine  (final  concentration  of  1  µg/mL)  twenty  five 
minutes before further processing. 3 drops of colchicine (concentration of 
1  µg/mL)  were  added  to  TC199  tubes  25  minutes  before  further 
processing.  The  cultured  tubes  were  centrifuged  at  1000  rpm  for  10 
minutes,  followed  by  removal  of  supernatan.  Warm  (37°C)  hypotonic 
solution  KCL  0.075M  was  added  to  the  cell  pellet  followed  by 
resuspending of the solution and incubation at 37°C in waterbath for 15-30 
minutes. Subsequently, the cell suspension was centrifuged at 1000 rpm 
for 10 minutes, followed by removal of suppernation and slow addition of 
5 mL Carnoy’s solution (3:1 methanol:acetic acid glacial) through the tube 
wall, then shaken well. These steps were repeated continuously untill a 
clear  precipitation  appeared.  Subsequently,  the  fresh  Carnoy’s  solution 
was added to suspend the residue. After that, two drops of cell  suspension 
were droppled onto a glass slide of 20 cm, then stored for 72 hours.  The 
aged slide was rinsed in water, put into a warm (37°C) Hanks solution, 
then moved into a 0.1% trypsin solution (in warm Hanks buffer) for 10-25 
seconds, and finally rinsed again with water. Subsequently, the slide was 
submerged with Giemsa 10% staining in buffer phosphate pH 6.8 for 1 
minute for GTG banding staining. 
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Appendix II: 
DNA Isolation 
 
Methods: 
DNA extraction was performed by the Salting Out methods as described 
by Miller et al (Miller et al., 1988).
 EDTA frozen blood was transfered 
into 50 mL tube. A total of 5-10 ml NH4CL lysis buffer was added to the 
blood samples and then left for incubation by room temperature for 10-30 
minutes.  The  tube  was  centrifuged  for  5  minutes,  3000-3500  RPM. 
Supernatan  was  removed  subsequently  NH4Cl  lysis  buffer  was  added. 
This  steps  was  repeated  three  times.  Two  mililiter  of  TE  lysis  buffer, 
Proteinase-K  10 mg/mL  and 100  ul 10% SDS  was  added  to the white 
palet, followed by incubation at 50
oC for 24 hours. Approximately one 
third volume NaCl 6M suspension was added followed by centrifuge at 
4000  RPM  for  10  minutes.  Supernatant  was  collected  in  a  new  tube, 
followed  by  addition  of  100%  ethanol,  twice  the  volume  of  the 
supernatant. DNA, present as a white substance, was taken for washing 
with 70% ethanol, then transferred into a 1.5 mL tube. The tube was left 
open for at least one hours to evaporate the excess of ethanol. DNA was 
resuspended in TE buffer.  
 xxvi 
 
Appendix III: 
FMR1 gene amplification 
 
Methods: 
Primers were designed in the (CGG)n flanking sequences of the FMR1 as 
described by Fu et al. (Fu et al, 1991). The forward primer was unlabelled 
and the reverse primer was 5’- labelled with FAM. Primer sequences are 
forward primer: 5'-GCT CAG CTC CGT TTC GGT TTC ACT TCC GGT-
3', and reverse primer: Fam 5'-AGC CCC GCA CTT CCA CCA CCA 
GCT CCT CCA-3'. Approximately 100 nanogram DNA was amplified in a 
reaction mix containing  2 µL of 10x Pfx amplification buffer, 0.6 µL of 
50 Mm MgSO4, 8 µL of enhancer solution, 0.5 µL of 10 mM dNTPs, 0.6 
µL of forward primer, 0.6 µL of reverse primer, 0.3 µL of Platinum Taq 
polymerase, and  6.4  µL  milliQ  in  a  20  µL  final  reaction  volume.  The 
reaction was initiated by denaturation for 3 minutes at 95°C, followed by 
31  cycles  of  15  seconds  denaturation  at  95°C,  2  minutes  annealing  at 
64°C, and 2 minutes elongation at 75°C. A final elongation step was set  at 
75°C for 10 minutes. 5 µL loading dye was mixed with 5 µL of PCR 
product  and  loaded  on  a  2%  agarose  gel  for  3  hours  at  120  volt.  All 
samples gave PCR product, so Southern Blot was not performed.   
 
Fragment length analysis: 
Principle: 
In  DNA  fragment  analysis,  a  mixture  of  fluorescent  labeled  DNA 
fragments were resolved into its constituent parts on the basis of molecular 
weight. After this, a profile was created.  
Method: 
One  microliter  of  PCR  product  was  mixed  with  0.3  µL  LIZ  500  size 
standard marker and 8.7 µL formamide. The samples were denatured by 
heating at 100C for two minutes. Then, the fragment size was measured by 
capillary electrophoresis on the ABI 3730 Analyzer. After the run, the data xxvii 
 
were automatically be sent to the BioLIMS Database. Data was analyzed 
using Gene Mapper software version 4.0 (Apache Software). The fragment 
length were calculated by the following formula: 
CGG repeat = {(length of the peaks-282)/3} +23 xxviii 
 
Appendix: IV 
X-Chromosome Linkage Analysis 
 
Principle:   
Particular set of alleles at linked loci (haplotypes) of the X-chromosome in 
families  were  determined  by  use  of  highly  polymorphic  markers.  This 
method  based  on  automated  systems  using  fluorescently  labeled 
polymerase chain reaction (PCR) fragments that allow very precise allele 
calling.  This  method  used  one  primer  that  is  5’  end  labeled  with  a 
fluorescent dye. Then, forward primer with a 19-bp extension at its 5’ end, 
identical to the sequence of an M13 sequencing primer, a regular reverse 
primer and a third universal fluorescent labeled M13 primer were used to 
reduce the costs of genotyping with fluorescently labeled microsatellites 
This  primer  “tail”  gave  a  complementary  sequence  to  the  universal 
fluorescent  primer  starting  from  the  third  PCR  cycle,  producing  a 
fluorescent product that can be detected on an automatic DNA sequencer. 
In this case, instead of synthesizing one specific labeled forward primer for 
each microsatellite marker, only one universal labeled primer was needed  
(Figure 5; Oetting et al., 1995). This approach was known as multiplexing 
with tailed primers.  
These short-tandem-repeat markers were selected with an average distance 
of  10  cM  between  markers  and  a  heterozygosity  score  of  at  least  0.7.  
Primers and location of the STR markers are described in Table 3.  First, 
genomic DNA was amplified using the specific CA-repeat primers (in the 
first PCR), subsequently in the second PCR 1 l of the first PCR reaction 
was  amplified  with  an  M13  forward  primer,  labeled  with  one  of  four 
fluorophores (FAM/VIC/NED/PET) at the 5’ end (Oetting et al., 1995) 
and a M13 reverse primer with a 5’-GTTTCTT-3’ added to its 5’ end to 
reduced tailing. Samples were pooled and analyzed by the 3730 Analyzer 
(Applied  Biosystems).  Differences  in  length  of  the  CA-repeats  was 
measured and raw data was analyzed with Genemapper software (Applied xxix 
 
Biosystems) to determine the haplotypes that are inherited together in the 
families.    Two-point  LOD  scores  was  calculated  by  easyLINKAGE 
software (Hoffman and Lindner, 2005). 
 
Table 21. Markers sequences used for X-Chromosome Linkage analysis   
Markers  Forward primer 5’>3’  Reverse primer 5’>3’  Location 
DXS8022  Tggaaactaatgcagcatgtc  aagtcccattttagccaacc  Xp22.2 
DXS7110  Gcacaaaggaggaaccaacc  tcggcttgtttaaatggtcct  Xp22.11 
DXS1036  Tgcagtttattatgtttccacg  gccattgataagtgccagat  Xp21.1 
DXS8090  Atcccccaaagaaccaagaa  caagggtgaaattccatcaca  Xp21.1 
DXS8012  Tttggaaggcggacataaac  aacaagaagcttagcaagccc  Xp11.4 
DXS1003  tgtgtgtgagtgagggagagag  agaagccgttattggtggac  Xp11.3 
DXS1199  ggtgactgactctgtggc   tggagtgaaatcaacatttaacata  Xp11.22 
DXS990  agctatatgaccagtacaaacatac   gacagaagggacatcaactc   Xq21.32 
DXS8096  attgggaaggtcatctcag   tcatgtgagccagttcttg   Xq22.2 
DXS1220  agcgagagtctgacccac   ggggcctataaaatggag   Xq23 
DXS1212  Aacagctcattttgtgtcatgg  tgacccagagaagtggaacc  Xq25 
DXS1047  Ccggctacaagtgatgtcta  cctaggtaacatagtgagaccttg   Xq25 
DXS1227  agaggtccgagtcttccac   ataagggtttactcccccaa   Xq27.2 
DXS8043  Ttggcaaagagtacaggcag  tctcagaaacatttggttaggc  Xq27.3 
DXS1193  aattctgactctggggc   ttattttaaggtgagtatggtgtgt   Xq28 
DXS1073  ggctgactccagaggc   ccgagttattacaaagaagcac   Xq28 
 
First PCR: (protocol by Zonneveld, 2009)    
For the first PCR, an input of 40 ng of genomic DNA was used. A reaction 
mixture was added containing 2.5 µL 10x PCR Buffer, 1 µL MgCl2 50 
mM (final concentration of 2 mM), 0.5 uL dNTPs 10 mM, 0.5 µL forward 
primer, 0.5 µL reverse primer, 0.1 µL Invitrogen Taq polymerase and 17.4 
µL milliQ. The reaction was initiated  by denaturation for  5 minutes at 
95°C,  followed  by  30  cycles  of  15  seconds  denaturation  at  95°C,  15 
seconds annealing at 58°C, and 45 seconds elongation at 72°C. A final 
elongation step was set  at 72°C for 10 minutes. Five microliter of each xxx 
 
sample was loaded on an 1,5% agarose gel to confirm amplification of the 
desired fragment. 
 
Second PCR: (protocol by Oostrik, 2009)   
Every CA-repeat marker was fluorescently labeled in the second PCR with 
a  labeled  forward  primer  (FAM/NED/VIC/PET).  CA-repeat  markers 
labeled with the same fluorophore, differed at least 40 bp in amplicon size. 
Two microliter of PCR product for the first PCR was taken for the second 
PCR.  A reaction mix consisting of 1 µL 10x PCR Buffer, 0.4 µL MgCl2 
50 mM (with final concentration of 2 mM), 0.2 uL dNTP 10 mM, 0.2 µL 
fluorescent labeled forward primer (FAM/VIC/NED/PET), 0.2 µL M-13 
pigtail reverse primer, 0.04 µL Invitrogen Taq polymerase and 5.96 µL 
milliQ. The reaction was initiated by denaturation for 5 minutes at 95°C, 
followed by 15 cycles of 15 seconds denaturation at 95°C, 15 seconds 
annealing at 50°C, and 45 seconds elongation at 72°C. A final elongation 
step was set  at 72°C for 10 minutes. Five microliters of each samples was 
mixed with  5 µl loading  buffer and  loaded on an 1,5% agarose  gel  to 
confirm amplification. 
Up to four different markers of the same sample were pooled (1 µl  of each 
marker).  Seven  point  five  microliters  formamide  and  0.5  µl  of  LIZ 
standard was added to 2 µl of pooled sample of the second PCR, final 
volume of 10µl. Samples were analyzed with the 3730 Analyzer (Applied 
Biosystems). Raw data was analyzed by Gene Mapper software (Apache 
Software) to determine haplotypes. Two-point LOD scores were calculated 
by Superlink (Fishelson and Geiger, 2002), and exclusion mapping was 
performed with GeneHunter PLUS v. 1.2 (Kong and Cox, 1997) integrated 
in easyLINKAGE (Hoffman and Lindner, 2005). Inheritance mode was set 
at recessive inheritance, disease allele frequency was set at 0.001, and full 
penetrance was assumed. 
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Appendix V: 
X-Chromosome inactivation (XCI) analysis 
 
Methods: 
Assays of XCI may be performed by  direct approach using  expression 
analysis  that  requires  RNA,  or  indirect  approach  with  DNA-based 
methylation analysis (Allen et al. 1992). Numerous methylation assays of 
XCI have been described with numerous technical approach, for example: 
conventional polymorphisms in the phosphoglycerate kinase (PGK) and 
hypoxanthine phosphoribosyl transferase (HPRT) genes (Vogelstein et al. 
1987 and Maestrini et al. 1992) and others more informative VNTR in the 
DXS255 locus recognized by the probe M27P (Boyd and Fraser, 1990) or 
microsatellite (Allen et al. 1992) markers.  All of these methods rely on 
two  basic assumptions: the presence of a polymorphism to discriminate 
between  the  maternal  and  the  paternal  X-Chromosome  and  a  different 
methylation  pattern  on  the  active  versus  the  inactive  X-Chromosome.  
However, considering that allelic difference are needed in these test, assay 
with  highly  polymorphic  loci are  desirable.  Thus,  methylation  study  in 
FMR1  and  AR  loci  were  used  in  this  study  considering  the  high 
heterozygosity (more than 90% heterozygosity of AR loci polymorphism 
in females  (Allen et al. 1992) and -65% heterozygosity for the FMRl CGG 
repeat (Fu et al. 1991)) compared to other locus (30% heterozygous in 
PGK probe, 18% heterozygous in HPRT probe and 90% heterozygous in 
M27I probe in those situations that provide enough DNA to perform both 
Southern analysis and PCR) previously described (Allen et al. 1992). 
 
X-Chromosome inactivation analysis: FMR1  
Principle: (Carrel and Willard, 1996)  
An assay based on methylation status at the fragile X mental retardation 
gene,  FMRl,  was  used  to  examine  the  pattern  of  X-chromosomal 
inactivation.  Digestion  of  genomic  DNA  with  BamHI  was  used  to  cut xxxii 
 
genomic DNA in order to improve PCR efficiency. This was followed by 
digestion with HhaI. Digestion of genomic DNA with this methylation-
sensitive enzyme cleaved two restriction sites near the CGG repeat of the 
FMRl-repeat of unmethylated (active X chromosome), but did not digest 
these sites on the methylated X (inactive X-chromosome). After digestion, 
a PCR, using primers that flank the CGG repeat site of the FMRl gene, will 
result in amplification of only undigested alleles, (the methylated inactive 
X-chromosomes)  (figure  24).  Amplification  of  the  hypervariable  CGG 
repeat made differention of alleles in heterozygous samples possible, while 
the relative signal ratio of alleles was used to assess the randomness of X-
chromosome inactivation. X-chromosome inactivation patterns would be 
defined as skewed if there is >80% skewing. 
 
 
Figure  24.  Methylation  assay  of  X-chromosome  inactivation  based  on 
PCR analysis of the 5’ untranslated part of FMR1. HhaI is not capable to 
cut the methylated sites on the inactive X-chromosome (Xi), thus allowing 
PCR amplification. On the other hand, digestion at either or both sites on 
the active X-chromosome will not result in amplification. 
 
Procedure: 
First,  informativity  of  FMR1  was  checked,  by  PCR  of  the  FMR1 
trinucleotide repeat as described in III.3.4. The next steps were performed 
if a sample was informative for the FMR1 trinucleotide repeat site. One xxxiii 
 
hundred twenty five nanogram of DNA from carrier females and a male 
control was digested overnight by 37°C with a combination of  BamHI and  
methylation-sensitive restriction enzyme HhaI as well as BamHI alone as a 
control. The first reaction included 125 ng of DNA with the following 
reaction  mix:  0.75  µL  BamHI,  0.5  µL  HhaI,  0.25  µL  Bovine  Serum 
Albumine (BSA), 2.5 µL of buffer NEB3, and 8.5 uL milliQ incubated 
overnight by 37°C. The control reaction included  12.5 µL of DNA mixed 
with a reaction mix of 1 µL BamHI, 0.25 µL Bovine Serum Albumine 
(BSA), 2.5 µL buffer NEB3, and 8.75 uL milliQ incubated overnight by 
37°C. Then, complete digestion was ensured by redigestion of the DNA by 
addition of half the amount of the previously described BamHI and HhaI 
reaction mixtures for 4 hours by 37°C. Subsequently, the enzymes were 
inactivated  for  20  minutes  by  65°C.  Five  microliters  of  each  digested 
sample was mixed with 5 µL of loading dye loaded on a 1,5% agarose gel 
to confirm the digestion. 
PCR  amplification  of  CGG  repeat  was  performed  with  5  µL  digested 
sample  mixed  with    2  µL  of  10x  Pfx  amplification  buffer  (Invitrogen, 
Breda, The Netherlands), 0.6 µL of 50 Mm MgSO4, 8 µL of enhancer 
solution, 0.5 µL of 10 mM dNTPs (Invitrogen, Breda, The Netherlands), 
0.6 µL of forward primer (5'-GCT CAG CTC CGT TTC GGT TTC ACT 
TCC GGT-3') ,0.6 µL of reverse primer (Fam 5'-AGC CCC GCA CTT 
CCA CCA CCA GCT CCT CCA-3'), 0.3 µL of Platinum Taq polymerase, 
and  2.4  µL  milliQ,  20  µL  final  volume.  The  reaction  was  initiated  by 
denaturation for 3 minutes at 95°C, followed by 32 cycles of amplification 
by denaturation at 95°C for 15 seconds, annealing at 64°C for 2 minutes, 
and elongation at 75°C for 2 minutes. A final elongation step was done at 
75°C for 10 minutes. 5 µL loading dye was mixed with 5 µL of PCR 
product and loaded on a 2% agarose gel (120 volt for 3 hours) to confirm 
amplification.   
Two microliter of PCR products was mixed with 0,5 µL LIZ 500 size 
standard marker and 7,5 µL formamide and analyzed on the ABI 3730 xxxiv 
 
analyzer. The raw data was analyzed using Gene Mapper software version 
4.0 (Apache Software).  
 
X-Chromosome inactivation analysis: AR method 
Principles: (Allen et al., 1992) 
This  method  was  a modification  of  the  human  androgen  receptor  (AR) 
gene  assay  described  by  Allen  et  al.  Inactivation  status  of  the  X-
chromosome  were  assessed  by  taking  advantage  of  the  favorable 
characteristics of   highly polymorphic trinucleotide repeat in the first exon 
of the human AR locus at Xq11–q12. The principle was similar with FMR1 
method,  only  the  repeat  is  more  informative  in  some  cases.  HhaI  will 
digest unmethylated DNA in the AR (CAG)n repeat region of the active X-
chromosomes  and  will  not  cut  methylated  sites  of  the  inactive  X-
chromosomes. 
 
Procedure : 
Primers were designed in the (CAG)n flanking sequence of the first exon 
of AR gene as described by Allen et al. The forward primer was 5' labelled 
(Fam). Primer sequences are: forward primer, Fam 5' TCC  AGA ATC 
TGT TCC AGA GCG TGC 3' and reverse primer, 5' GCT GTG AAG 
GTT GCT GTT CCT CAT 3'.  
First we checked AR informativity. PCR was performed as follows:  1 µg 
DNA in 3 µL (AB) Buffer, 0.5 µL dNTPs, 0.6 µL forward primer, 0.6 µL 
reverse  primer,  0.3  µL  ampliTaq,  2.5µL  DMSO,  21.5  µL  water.  The 
reaction was initiated by denaturation for 2 minutes at 95°C, followed by 
30 cycles of 30 seconds denaturation at 93°C, 30 seconds annealing at 
55°C, and 30 seconds elongation at 73°C. A final elongation step was set  
at 73°C for 10 minutes. The next steps were performed when the AR repeat 
turned out to be  informative. 
Three micrograms of DNA dissolved in 70 uL milliQ from carrier females 
and a male control were digested for 6 hours by 37° with a combination of xxxv 
 
BamHI  and  methylation-sensitive  restriction  enzyme  HhaI,  as  well  as 
BamHI  alone  as  a  control.  First,  digestion  of  35  µL  of  DNA  with  a 
reaction  mix,  containing  1.5  µL  BamHI,  1  µL  HhaI,  0.4  µL  20  mM 
spermidine, 4 µL React4 was initiated by incubation for 6 hours by 37°C. 
The control reaction conditions were: digestion of 35 µL of DNA with a 
reaction mix, containing 2 µL BamHI, 0.4 µL 20 mM Spermidine, 4 µL 
React4 incubated for 6 hours by 37°C.  Digestion was confirmed by gel 
electrophorese:4 µL digested sample and 2 µL bromphenol blue 10x  were 
loaded on an 0.8% agarose ME Seakem gel (1 hour, 120 volt). 
PCR amplification was performed on 3 µL of digested sample under the 
following conditions: 3µL (AB) buffer, 0.5 µL dNTPs, 0.6 µL forward 
primer, 0.6 µL reverse primer, 0.3 µL Taq (PE), 2.5 µL DMSO, 19.5 µL 
milliQ. The reaction was initiated by denaturation for 2 minutes at 95°C, 
followed by 30 cycles of 30 seconds denaturation at 93°C, 30 seconds 
annealing at 55°C, and 30 seconds elongation at 73°C. A final elongation 
step was set  at 73°C for 10 minutes. 
Five microliter of orange G loading buffer was mixed with 5 µL of PCR 
product and loaded on an 1% agarose gel (ME Seakem) (200 volt for 45 
minutes in 0,5 TBE) to confirm amplification of the AR repeat.   
One  microliter  PCR  products  was  mixed  with  0,3  µL  LIZ  500  size 
standard  marker  and  9  µL  formamide  and  analyzed  on  the  ABI  3730 
analyzer.  The  raw  data  were  analyzed  using  Gene  Mapper  software 
version 4.0 (Apache Software). 
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Appendix VI: 
Candidate Gene Selection 
 
Promising candidate genes were selected in linkage intervals on the X-
chromosome. The UCSC Genome browser database was used to extract all 
UCSC  genes  in  the  linkage  intervals.  Prioritizing  candidate  genes  was 
performed  by  use  of  two  independent  bioinformatics  tools  (ToppGene 
{available at at: http://toppgene.cchmc.org/} and Endeavour {available at: 
http://homes.esat.kuleuven.be/~bioiuser/endeavour/index.php}; Chen et al, 
2007; Tranchevent et al, 2008) and secondly, by manual selection based on 
the expression in brain/neuronal tissues, homology with known MR genes, 
involvement in the same protein network as already known MR genes, and 
gene methylation status. 
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APPENDIX VII: 
Proposed Workflow for XLMR Studies 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
   Anamnesis : X-linked pedigree, clinical history, exclude acquired factors 
   Physical Examination 
   Blood drawn 
Conventional 
Cytogenetic analysis 
Fragile-X exclusion : 
PCR of FMR1 repeat 
 
Linkage analysis 
Linkage Interval 
Candidate gene selection 
Sequencing 
Family with multiple MR individuals  
Gross Chromosomal 
Aberration 
Fragile-site 
detection 
DNA analysis 
(-)  (+)  (+)  (-) 
No CGG 
 expansion 
 
CGG 
expansion 
 
X-chromosome 
Inactivation analysis 
 
Array 
Skewed  
XCI 
No Skewed 
XCI 
Mutation  No mutation 
Next Generation 
Sequencing 
Coppy Number Variation xxxviii 
 
APPENDIX VIII: 
Proposed Workflow for X-linked Hydrocephalus and MR 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
   Anamnesis : X-linked pedigree, clinical history, exclude acquired factors 
   Physical Examination 
   Blood drawn 
Conventional 
Cytogenetic analysis 
Fragile-X exclusion : 
PCR of FMR1 repeat 
 
Gross Chromosomal 
Aberration 
Fragile-site 
detection 
DNA analysis 
(-)  (+)  (+)  (-) 
No CGG 
 expansion 
 
CGG 
expansion 
 
Family with familial hydrocephalus and MR  
Linkage analysis 
Linkage Interval 
Candidate gene selection 
Sequencing 
X-chromosome 
Inactivation analysis 
 
Array 
Skewed  
XCI 
No Skewed 
XCI 
Mutation  No mutation 
Next Generation 
Sequencing 
Coppy Number Variation 
Sequencing known genes: 
- L1CAM 
- AP1S2 
 
No mutation  mutation xxxix 
 
APPENDIX IX: 
Physical Examination Form 
 
Dr:        DATE:     LOCATION :  
 
 
Family/proband 
Gene  Mutation  DNA/fam.nr.  Laboratory 
       
 
 
Clinical photographs 
yes/no 
Archived where  Consent patiënt/parents for use in 
teaching and/or scientific 
publications/meetings 
 
Clinical genetic conclusion  
 
Diagnosis  Recurrence risk  Remarks  
1     
2     
3 
 
   
 
 
Relevant patiënt organisation:     
 
 
 
Literature given to patiënt/parents: 
 
 
 
NAME AND  ADDRESS OF REFERRING/TREATING DOCTORS 
 
  Name  Specialism    Address 
1. 
2. 
3. 
 
Date  Name supervisor  Signature of supervisor 
     
     
     xl 
 
PEDIGREE 
 
Consanguinity yes/no 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xli 
 
HISTORY 
 
 
Conception  
 
Exposition by profession/recreational? 
 
Profession of man/father:    Profession of woman/mother: 
 
Pregnancy: 
                                       
fluxus      diabetes mellitus   
fever      medicines 
skin problems    smoking 
infections      alcohol 
trauma      X ray/radiation 
toxicosis      other intoxications 
 
 
Prenatal care from ………weeks GA by: 
Prenatal diagnosis (indication and results): 
Ultrasound examination (indication and results): 
 
 
Delivery: by whom  where 
gestational age  spontaneous 
induction    artificial labour 
position   duration      Apgar 
score 
amniotic fluid  umbilical cord    placenta 
W              (P:         )  L:               (P:         )     OFC:               
(P:          ) 
asphyxia    icterus      
artificial ventilation:  how long in hospital: 
 
Neonatal period: 
feeding problems 
hypotonia 
 
 
Psychomotor development:        regression yes/no 
laughing                   grasping        rolling over   
making noises    sitting with help    sitting without help 
standing   walking      speech 
social contact      school         
behaviour xlii 
 
Past ilnesses/admissions/operations 
 
 
 
 
 
Paramedical treatment (physiotherapy, speech therapy etc.) 
 
 
 
 
Prescribed medicines 
 
 
 
 
 
SPECIFIC HISTORY  
 
 
 
 
 
 
 
 
 
 
 
 xliii 
 
EXAMINATION    Date:      Age at examination: 
 
General aspects 
 
Bodily habitus:          Developmental level 
            motor : 
            cognitive: 
   
 
 
 
 
         
Stature in proportion: yes/no 
 
 
Measurements           P/SD                     P/SD 
weight   
 
length/height 
 
OFC 
 
spanwidth 
 
US/LS 
 
Sitting height 
 
 
ICD 
 
OCD 
 
IPD 
 
Palp. fissures  
               
Corneadiameter  
                
 
fontanel 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OD 
OS 
 
 
 
 
 
    Ear length 
           
 
Nipple distance 
 
 
Chest 
circumference 
 
 
Penile length 
 
 
Testis volume  
              
 
Foot length  
            
 
Hand length  
            
 
Palml ength  
            
 
finger III length  
                   
AD 
AS 
 
 
 
 
 
 
 
 
 
 
 
ri 
le 
 
ri 
le 
 
ri 
le 
 
ri 
le 
 
ri 
le 
   xliv 
 
HEAD 
 
General:      form                micro/retrognathia   
 
      forehead        mimics     
 
      mid face             
 
Eyes    :   position          form 
 
      hypo/hypertelorism      tele/epicanthus 
      blepharophimosis ri/le      ptosis ri/le 
      microphthalmos ri/le      iris coloboma     
 
      cornea        eye lids 
 
      eye colour        eye movements 
 
Ears    :  position        fistula 
 
      form        appendages 
 
Nose    :  form        philtrum 
 
      choanae       
 
Mouth    :  size        palate (uvula) 
 
      lips        teeth 
 
      tongue        gingiva 
 
Neck  :  :  webbing        hairline 
 
      fistula        movements 
 
 
 
 
TRUNK 
 
Thorax    :  form        heart 
 
      mammae        lungs 
 
      nipples 
 
       
Abdomen  :  liver        spleen     
 xlv 
 
      kidneys        hernia 
         
      diastasis mm. recti      abdominal wall         xlvi 
 
Back    :  kyphosis/lordosis/scoliosis      spina bifida 
 
      sacrale dimple        anus 
 
Genitalia    :  puberty stages (Tanner)  A  M    P  G 
 
      testis 
 
LIMBS 
 
Arms    :  proportions        upper arm 
 
      muscle tone        under arm 
 
      hands:  syn/poly/clino/camptodactyly   
     
          palm creases 
 
 
Legs    :  proportions        upper leg 
 
      spiertonus        lower leg 
 
      feet:  syn/poly/clino/camptodactyly 
           
          pes cavus/planus 
 
Hypermobility score: thumb to under arm  5th finger > 90
o   
  elbows > 10
o 
 
      knees > 10
o    hands to floor 
 
     
      Total ....../9 
Contractures? 
 
SKIN   
  Hair (incl.eyebrows, eyelashes)        sweating 
 
  elasticity              nails 
   
  pigment changes          others 
 
  bullae/ichthyosis/hyperkeratosis 
 
  vascular abnormalities 
 
 
NERVOUS SYSTEM 
 xlvii 
 
Summary 
 
 
 
 
 
 
 
 
 
Preliminary conclusion and differential diagnosis 
 
 
 
 
 
 
 
 
 
 
Additionnal investigations/management 
 
 
 
 
 
 
 
Results of additionnal investigations (with dates!) 
 
biochemistry/clinical chemistry 
 
 
cytogenetics 
 
 
DNA 
 
 
imaging 
 
 
IQ 
 
consultands 
 
   